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THE EXPECTATION GAME OF FINNISH ICT AND BIOTECHNOLOGY FIRMS 
- Systematic factors behind high technology company growth estimations
Objectives of the Research
This research aims to find out the systematic factors behind the high revenue 
expectations of biotech and information and telecommunication sector 
companies. The focus of the empirical research is on the R&D-intensive firms, 
which have known to present high estimates of growth in revenues and later on 
in earnings. The paper seeks to find out the impact of firm- and project-specific 
factors on the level of turnover expectations. In addition, past estimates are 
analyzed based on previous forecasts and the follow-up information. The study 
aims to seek answers to the expectation game in high tech industries and how 
the expectations have materialized. The ultimate goal is to discuss whether the 
turnover targets are realistic in Finnish ICT and biotechnology industries.
Data and Methodology
The econometric model is based on the data obtained from the National 
Technology Agency of Finland, Tekes. The data consists of revenue 
expectations of 256 ICT and 80 biotechnology R&D projects. The time period 
for ICT projects is 1.1.2003-31.12.2003 and for biotechnology projects 
1.7.2002-31.12.2003. Multiple regression models are used to test seven 
hypotheses derived from earlier scientific research theories. In the latter part of 
the study the past performance of ICT and biotechnology turnover development 
is compared to the estimates given by the companies. The ICT sample is from 
Tekes follow-up data and includes 75 projects. In biotechnology, the history 
data is collected from those companies that are included in the 80 biotechnology 
R&D project holders studied in the first part of the research and who had 
projects accepted for Tekes funding in 1997-1999.
Results of the Research
The revenue estimations of ICT companies are unrealistic. Both the two 
econometric models constructed and the past performance of ICT companies’ 
turnover development support the conclusion. The realistic level of company 
turnover estimates would be only 20-30% of the original estimates. In 
biotechnology the expectations have not realized yet but the estimates have 
shrunk in size and postponed with years. I found some support for venture 
capital involvement, past R&D costs, exports and hot market condition when 
company growth factors are considered. However, the most significant impact 
on company growth has future R&D investments.
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1.1 Content and background
In the late 90’s there has been a significant move towards technology in the global markets. 
This shift coincided with the rise of Internet, which ultimately linked the uprising of new tech 
companies with the Internet. The definitions of new technology companies were somewhat 
ambiguous and far from clear-cut. What they had in common was that they were young, often 
with little or no revenues and they were making substantial losses. Despite of this the new 
tech companies incurred extraordinary increase in value. The so-called Internet-bubble 
reflected the unrealistic growth presumptions of the markets. The high-tech firms tended to go 
in public earlier than was normally the case. Without established products and markets the 
challenge was the estimation of the expected cash flows. However, even though normally the 
estimation of the growth rate in revenues is easier than estimating operating margins and 
expected cash flows, there is quite a challenge in making realistic assumptions concerning 
revenue growth rates, especially when it comes to new high tech companies without a track 
record. Despite that the Internet-bubble era is over, there still lays the challenge of the 
expectations game in the early phase high tech companies. The larger portion of company 
value being from future growth potential, the vulnerable is the firm to shifts in the 
expectations about future prospects.
The focus of this research is on Finnish biotech and information and communication (ICT) 
sector companies and the systematic factors behind the high revenues expectations. The 
ultimate goal of this research is to find out whether the turnover estimations of Finnish ICT 
and biotechnology high tech firms are realistic and whether they are explained by the 
systematic factors used in this study. Especially high tech companies in their early phases 
have difficulties to benchmark their excellence against current and forthcoming market 
situation. Without established products and the lack of experience of delivering goods from 
R&D phase to markets there is quite often a lack of congruence in the target turnover levels 
and the present situation of the companies. Quite often the market analysis done by the 
companies are scant, without evident link to company strategy and the target is vaguely a
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percentage share of world markets. Acknowledging the evident problems in the high tech 
business and the high risk incorporated in it, it is justified to question whether the target 
turnover levels painted by the company CEOs are realistic.
Firms in these sectors are usually highly R&D-intensive. Hermans and Tahvanainen in their 
recent study (2002) have studied the characteristics of Finnish small biotech businesses. In 
their research the R&D-intensive firms reported ‘4hat the more their costs contained R&D 
expenses, the higher their growth prospects were.” High R&D investments are important for 
future growth but probably not the only factor influencing company turnover estimations. 
From an investor point of view the high tech companies are interesting because the return of 
the investment could be extremely high when the “golden egg” is found. Venture capitalist 
(VC) could be seen as informed agents, which have the ability to identify promising start-ups. 
Naturally there is a quite a challenge for the venture capitalist to invest in right companies. 
Companies interested in getting venture investments need to present high turnover estimations 
to attract investors. Some of the companies might have the fundamentals right but some of the 
companies might not. High revenue expectations and VC investment could indicate a possible 
success story. In the finance literature the phenomenon is called the picking winners theory 
(Baum and Silverman, 2003).
Other systematic factor behind growth opportunities could derive its origin from 
internationalization, capital structure and prior turnover development of a company. Company 
growth prospects in small economies are usually related to export opportunities. There are 
also studies linking growth opportunities with the capital structure of a company. The 
negative relation between growth and leverage will be studied. In addition, the study aims to 
show that prior hot market condition (i.e. yearly increase in revenues) affect the CEOs view 
on future growth prospects.
This study seeks to find out the relevant factors behind high tech company growth prospects 
and build an econometric model to explain the estimated turnover levels of the companies. 
The aim is to test what proportion of the turnover levels estimated by the companies is 
explained by the models. The results obtained from the models will be used to find out the 
realistic level of turnover estimations in ICT and biotech. This study will seek differences and 
explain them in an industry level between ICT and biotechnology companies. ICT and biotech 
sectors are very different in nature and due to this they are very interesting groups for
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comparisons. The aim is to find out factors which could be relevant also in other business 
areas than in biotech and ICT. The data consists of 293 companies from bio and information 
and communication sector. The revenue expectations are project-based estimations. The data 
is gathered from the database of the National Technology Agency of Finland (Tekes).
The latter part of the study concentrates on analyzing the past performance of estimations 
from both industries. Data from Tekes is used to cover realized turnover performance of a 
smaller sample of companies from both sectors against their R&D project turnover 
estimations from past. It is shown how the past performance of companies support the results 
obtained from the econometric models.
This study contributes to the earlier scientific research on high tech company growth 
estimations with its combinatory approach of combining data of future turnover estimations 
with data on past performance of companies. To my knowledge only few academic studies 
have attempted this approach. The study provides also interesting information on company 
performance in two very important high tech industries in Finland. The data obtained from 
Tekes is unique in Finland and first time used for this kind of approach.
1.2 Motivations of the study
The motivation to do the study sparkled from the problems I confronted in my present work in 
Tekes. As a controller mainly in biotech industry - partly also in ICT -1 was puzzled by the 
turnover levels presented by the applicants. The turnover levels targeted by the small and 
medium size firms were extremely high compared to the size of the firms. In many cases the 
target figures were backed by quite overall market analysis done by the company itself or a 
professional market analysis company. One obvious reason for broad but not so focused 
market analysis is that R&D intensive firms are quite young and they lack sufficient track 
record and the products they are developing - especially in biotech - are quite distant from the 
markets. The demands and the challenges of the markets are not forcefully present in the 
R&D phase. This means that the target turnover figures are not based on the fundamentals of 
the product itself but the overall success rate of similar companies or similar products. The 
risk inhibited in the R&D is not so often taken into the consideration also in the target 
turnover levels. Normally the companies present only the upside view of the possible 
outcome.
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The companies might have the resources to do the R&D phase but they lack the experience 
or/and the resources to do the marketing phase needed for a commercially successful product. 
The company and project portfolio presented in this study include companies with high risk 
projects which naturally need to have high return profiles. The question I pose in the starting 
phase of the study is whether the target levels are realistic and do they have the fundamentals 
needed to back them up.
1.3 Objectives and research questions
The aim of this study is to find out the systematic factors behind small and medium size 
(SME) high tech companies’ growth prospects. The study concentrates on few key input 
factors to explain the growth prospects of the companies. By constructing econometric 
models I will try to analyze the realistic levels of high tech companies’ growth estimations. In 
the latter part of the study the accuracy of the estimations in both sectors are viewed against 
realized development with a smaller set of data.
The research questions to be answered are following:
1. Does firms with venture capital investment have higher growth estimates?
2. Are exports or export intensity1 related to growth rates?
3. Does R&D costs or R&D intensity explain high growth estimations?
4. Does high solidity indicate high growth prospects?
5. Does hot market condition (actual revenue increase) imply high growth?
6. Does projected future R&D investments as such or when related to company balance 
explain high growth estimations?
1 Intensity is calculated by dividing the independent variable by the company size factor e.g. exports divided by 
total revenue or R&D costs divided by the company balance
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7. Is company age related to growth prospects?
8. Based on history data, how has the estimations of biotech and ICT firms realized? Are the 
estimated turnover levels realistic?
9. How do the factors found differ between biotech and ICT sectors and what are the 
underlying reasons behind differences?
These questions will be answered by going through earlier scientific research and by testing 
the hypothesis created in accordance with the earlier research. The received results are later 
on discussed with the industry experts. The intention is to enrich the study via insights from 
the field and improve the understanding of the results. Also the dynamics behind the estimates 
are analyzed via a qualitative approach i.e. the turnover estimates are reviewed against the 
“Targeted business of the applicant” -section of the application where companies have 
analyzed the commercial potential of the projects
1.4 Structure of the study
The structure of the paper is the following. The next section will review the industry sectors 
in general. The aim is to have a solid understanding of the present situation in the biotech and 
ICT industry in Finland and also in a global scale. In addition, an attempt to further clarify the 
nature of the industries is made. The analysis of the industry conditions should first of all help 
to understand the unique characteristics of biotech and ICT sectors. It serves as a basis for 
analyzing the empirical results and also as a context for understanding the discussions with 
the industry experts.
In the third section I will go trough the related research theory in order to create the 
theoretical framework for the study. Based on the previous research the necessary hypotheses 
for the study are created. The forth section covers the description of the data and the 
methodology. In the methodology part the research design issues will be clarified. Finally the 
multivariate regression analyse is performed.
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The first part of the fifth section will concentrate on validating and examining the results. The 
latter part of the findings will concentrate on analyzing how the project based turnover 
estimates and the realized total turnover of the companies in biotechnology has developed. In 
ICT the estimations of the turnover of a R&D project is benchmarked against the actual 
development of the turnover according to a follow-up data. Next, the nature of the expectation 
game in the industries is compared in relation to the received results.
Finally, the sixth section will conclude the study and present further research topics.
2. Industry overviews
The intention of the industry overview section is to build a background for the rest of the 
study. Both industries are described quite broadly due to nature of this study. The overviews 
aim at describing the present state of the industries and the special features they incorporate. 
Irrespective of the fact that the empirical part includes only Finnish companies, the industry 
overview is partly international in nature. Both industries are liable to global market forces.
2.1 Biotechnology
The term biotechnology is widely used in many instances. Biotechnology is more of a mixture 
of separate technologies than a separate science itself. For statistical purposes a single 
definition has been created in OECD in 2002: “The application of science and technology to 
living organisms, as well as parts, products and models thereof, to alter living or non-living 
materials for the production of knowledge, goods and services” (Hermans and Luukkonen 
2002). Word like biotech is truly a “buzz-word” used almost in any context. In this study it 
refers to companies that utilize biotechnological innovations in their own application areas or 
just as a shortening for the word biotechnology.
The paper of James Watson and Francis Crick 50 years ago on the structure of DNA has been 
considered as a beginning of modem biotechnology (OECD, 1999). Since those days the 
development of modem biotechnology has been sky-rocketing. Biotechnology or life sciences 
have been regarded as the new sunrise industry of the 21st century after the reign of 
information technology in the 1990s (Ernst & Young, 1998). The foundation of the first
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venture capital backed biotech company, Genentech, in 1976 has been considered as the 
starting point of commercial biotech industry. The early development of industry was 
controlled by the USA and particularly Silicon Valley, California. In 1980s biotechnology 
sector was gradually creating alliances with the big pharmaceutical companies. Last decade 
was the time for expansion, growth and legitimacy as companies succeeded to get products 
out of their pipelines (Arojärvi, 2001). Also initial public offering i.e. IPO window was open 
for biotech’s, especially in the turn of the century. Year 2000 was a good vintage for 
biotechnology: high valuations were acceptable and there was funding appetite for technology 
platforms. Excitement of humane genome sequencing and impact of genomics prevailed and 
high cash bums and long period to profitability were acceptable and exits achievable
Years 2001-2003 have been difficult for the global economy in general. The hangover of 
biotech itself was partly due to lowered valuations, technology platforms being out of favour, 
IPO window closed, genomics showing no fast results, VC funding tightened in addition to 
global economy decline and uncertainty of war (Afganistan, Iraq). The road to recovery after 
three years of bear market is challenging but it is seen as the survival of the fittest. The high 
risk factors included in biotech were disregarded by some VCs; early stage investments 
demands high return rates. Growth prospects of too many companies proved to be unrealistic 
(Rushton, 2003).
The fundamentals for biotech business are however still positive. Companies are reaching 
profitability, overall market is recovering and IPO window is opening slowly. European 
biotech revenues have been increasing steadily for many years in a row. (Gillin, 2003) Market 
capitalization of biotech companies has increased almost 50 % from the end of 2002. The 
return of the bull market has brought back biotech valuations. Near term drivers have been 
product approvals and sales and earnings growth exceeding expectations (Ullman, 2003).
2.1.1 Industry dynamics
In the previous chapter the definition of biotechnology was discussed. In this chapter an effort 
is made to describe the industry dynamics in more detailed way. Burrill & Company, a life 
science merchant bank, has in their yearly biotech report divided the industry in a following 
way: Health care, Diagnostics, Nutraceuticals, Agbio and Biomaterials/Bioprocesses. This
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classification is quite clear and it will be used here as a framework for describing the industry 
dynamics. There are many other classifications like the ones of Lievonen (1999) and Oliver 
(2000). The division is usually made according to the type of industrial application developed 
or the technology used by the sector.
Healthcare and especially pharmaceutical industry have been quite commonly studied objects 
in biotech industries. The pharmaceutical sector develops new medicines against diseases. 
The drug discovery industry has potential to save lives and improve the quality of human life. 
Despite the successes in the industry many diseases remain as a mystery. The absence of cure 
increases healthcare costs and due to the aging of the population, the costs are ever- 
increasing. Pharmaceutical industry is dominated by the large pharmaceutical companies - 
also known as “big pharma”. In many cases drug discovery phase is done by a small R&D- 
intensive company but due to their limited resources a licence deal with a big pharma 
company is usually necessary. The pharmaceutical research direct the way of the future 
business possibilities in the industry. The number of drug targets is expected to increase. All 
the drugs on the market target fewer than 500 human molecules. The sequencing of the 
human genome will increase this number to several thousands. However, the mapping of 
human genome is just beginning. The future of the industry lies not in the genes controlling 
the production of proteins that makes us humans than in understanding the proteins 
themselves. (Branbäck et al., 2001)
Diagnostics industry is divided into 5 major segments: Nucleic Acid Testing (NAT), Clinical 
Chemistry, Immunoassays, Whole Blood Glucose (WBG) and Tissue Analyses. The fastest 
growing segment of the diagnostics industry in 2002 was Molecular diagnostics. In 2002 
more than one million genetic tests were done and it is believed that in 2006 that figure could 
rise to ten million. Molecular diagnostics can help to identify correct responders to a 
particular therapeutic, to test adverse reactions and monitor chronic illnesses. Growth of the 
industry is dependent on several factors: the development of genomics and proteomics, 
decreasing cost of drug development, better utilization of therapies, need to reduce adverse 
drug reactions and the new approach for personalized medicine.
The global nutrition industry, i.e. nutraceuticals is a mixture of sound science and consumer 
needs and the industry is growingly capturing the attention of people interest in wellness, 
health, fitness and diet. The growing awareness of healthy living habits, the aging of
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population and the self-interest of people wanting to control their way of life has together 
with rising health care costs inspired people to seek preventive measures. One of the biggest 
problems is obesity. 1.8 billion people worldwide suffer from it. Compared to pharmaceutical 
industry where researchers start first with science, in the nutraceutical industry the starting 
point is the unmet consumer need. However, the industry is from a scientific point of view 
also challenging. It is estimated that the functional food and dietary supplements market are 
growing approximately 8-10% per year. The industry has however a credibility problem 
because some of the products offered has not been backed by scientific rigour.
Agribusiness or Agbio has been in turbulence because of continuing debate over genetically 
modified organisms (GMOs), while the critics of European Union has kept GMO-based 
products out of the markets in Europe. Also the use of biopharming has been questioned for 
the same reasons as GMOs. Both methods are accused of potential contamination of 
traditional crops. The advocates of GMOs point out that genetically modified food could be 
the answer for third world malnutrition problems, even more so when population is increasing 
drastically.
The last industry sector according to Burrill & Company’s classification is biomaterials and 
bioprocesses. The driving force for traditional and novel manufacturing processes of using 
biotechnology is to find alternatives for traditional petroleum and other chemical-based 
materials and processes, consumers demanding for stable and low cost alternatives for oil, gas 
and petroleum. Similarly, markets for biomaterials and bioprocesses are estimated to growth 
because of climate effects like global warming. Also by complying with Kyoto Accords new 
and stricter environmental rules are coming into force. Industrial biotechnology is called “The 
Third Wave in Biotechnology”. The first wave included innovations in health care, the second 
innovations in agricultural biotech. The opportunities in the industry include bio fuels 
(ethanol, bio diesel, and hydrogen), bio-based materials, novel biocatalysts, polymers, 
medical biomaterials, tissue engineering and bio-absorbable products. (Burrill & Company, 
2003)
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2.1.2 Risks and opportunities of biotechnology2
Biotech industry has many typical features that need to be discussed before going to the 
Finnish biotech industry specific factors. Some of the most well known features of biotech are 
presented which should help to understand the industry itself. Biotech compared to other high 
tech industries has similarities but the dynamics of biotech has also some unique 
characteristics.
Technological risks. It has been said that being in the biotechnology is like riding a roller 
coaster. The industry is characterized as very challenging from a business point of view. For 
example in pharmaceuticals, drug development is a risky business with long R&D times (12- 
15 years) and an extremely high cost until the drug is in the markets ($500-600 million). The 
costs are related to strict regulatory policies of national drug administrations. The drugs are 
required to go through series of tests in humans before clearance to the markets. The drug 
development business normally requires big muscles so that the high failure rate of drugs is 
possible to endure. From investor point of view the industry is for the most cool-minded and 
patient and normally the break-even is not in the foreseeable future. The companies without 
any blockbuster products are normally making losses and the value-added lays in the 
company R&D pipelines. However, the magnitude of rewards is almost impossible to imagine 
when a break-through has been realized. In spite of possible blockbusters the technological 
uncertainty and the risk inherent in it is the most important feature of the industry.
Industry turbulence and centres of scientific excellence. The biotechnology industry is 
characterized by a very dynamic environment including big companies and small spin-offs 
from universities and large companies. Like in many emerging industries biotechnology is in 
its development phase. The young industry is incurring many entries and exits of companies 
moulding the look of the industry all the time. Biotechnology industry is closely linked with 
academic world not only through spin-offs but also through scientific collaboration.
Patenting and international regulation. Patenting is very important feature of the industry due 
to the nature of the inventions. Patents provide exclusivity rights for the product for a limited
2 The classification adapted from Gustafsson (2000) and Arojärvi (2001).
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time span. Patenting time affects product life cycle and cash flows obtained from products. 
First mover advantage is very important in the industry because of patenting. The average 
protection time is 20 years and when the R&D process normally takes approximately a decade 
the effective product life cycle is ten years. International regulation has a certain guidance 
effect on the industry through the approval policy of national drug administrations. For 
example, The Food and Drug Administration (FDA) in US is closely followed world wide in 
the industry when it comes to its approval policy of drugs. In EU European Medicines 
Evaluation Agency (EMEA) carries out regulatory system of monitoring and approving 
medicinal products.
Global markets and high entry barriers. Biotechnology industry is global in nature. The 
problems of the globe from a biotech perspective are borderless. Global perspective means 
that companies need to have considerable amount of capital, world wide network of offices 
and a large sales force or distribution networks to be large enough. For a smaller biotech 
company this normally means that they are not able do everything themselves. Out-licensing 
of manufacturing and/or marketing are typical ways for a smaller R&D-company to proceed. 
Other high entry barriers are proprietary technology, capital requirements, access to 
distribution channels and access to skilled personnel.
Venture capital (VC) and national policies. Venture financing is extremely important factor 
in biotech because of long development times and high bum rates. VCs usually also guarantee 
an access to later stage financiers through their networks or carry the company until IPO is 
finalized. National policies and biotechnology are closely interrelated because of the nature of 
the industry. The promising outlook of the industry is making the governments increasingly 
interested in biotech. However, advances in science are making governments and societies in 
some cases also wary of the possible threats incorporated to new inventions.
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2.1.3 Biotechnology in Finland
The study made by Hermans and Luukkonen (2002)3 find out that by the end of 2001 there 
were 119 firms active in biotechnology in Finland (Fig. 1). In 2003 active firms numbered to 
141 (Luukkonen, 2004a).
Figure 1.
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Source: Hermans and Luukkonen (2002)
From a European perspective Finnish biotech firms have emerged later than firms in the UK, 
France, or so called Medical Valley i.e. Sweden and Denmark (Table 1):
3 The study is based on a survey conducted by Etla and Etlatieto Ltd. The conducted survey represents quite well 
the total population of Finnish biotech companies.
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Table 1.
The distribution of biotechnology firms in Europe by year of foundation
Founded Finland UK Germany France Sweden EU15
- 1991 26% 33% 20% 32% 38% 31%
1991-1995 38% 25% 23% 25% 26% 25%
After 1995 36% 42% 57% 43% 36% 44%
No of firms 105 448 504 348 235 1930
Source: Hermans and Luukkonen (2002)
From a geographical point of view the largest centres of biotechnology industry are in 
Helsinki and Turku regions. Other regional centres listed in magnitude are in Kuopio, Oulu 
and Tampere.
Hermans and Luukkonen find out that companies that were established between 1997-2001 
67 % were spin offs from academia or other research institute and 19 % from another 
company.
Figure 2.
Sectors of activity among Finnish Biotech Firms
a Founded before 1391 






Source: Hermans and Luukkonen (2002)
The Finnish biotechnology firms are most active in pharmaceuticals and diagnostics (Fig. 2).
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Figure 3.









Source: Hermans and Luukkonen (2002)
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Figure 3 is very good example of the current situation in biotechnology in Finland. The young 
R&D intensive firms are mainly making losses. However, the investments in R&D are 
expected to yield very high annual growth rates in revenues especially in the youngest cohort 
(Table 2).
Tabic 2.
Anticipated annual growth rate of Finnish biotech firms (weighted by firm size).
Anticipated annual growth rate of turnover (5 years)




Source: Hermans and Luukkonen (2002)
The Finnish bio industry is in early stage of its development and the estimates given by the 
companies would indicate a lot of commercial potential. The overall sentiment in the industry 
is that major international deals are soon to be realized. Some activity to this direction was 
already occurring in 2003. Main part of the youngest firms has their products on a
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development phase and need still a great deal of financing until marketing phase. Limited 
resources of Finnish VC money mean that international venture financing is required in the 
future. Another important point is that the industry needs success stories, that is, companies 
reaching break even point to strengthen the credibility of the industry. At the moment there 
are only potential success stories. However, in spring 2004 good news from companies like 
Ark Therapeutics Ltd (IPO spring 2004) and Biotie Therapies Oyj showed that the R&D work 
done in the companies is valued in the markets.
2.2 Information and communications technologies
The role of information and communication technology (ICT) industry in economic growth 
has been in the spotlight for many years. ICT sector like biotech has been a hot topic; the 
driving force in both industries is high technology. Both sectors were in the forefront when 
stock markets soared in the late 90s. After the market hangover they have both suffered from 
the economic downturn. ICT’s importance has grown in global economy but in spite of that 
the production, diffusion and use of ICT vary considerably between and also within countries 
(OECD, 2002).
The complete definition of ICT sector has been under development for years. In 1998 the 
sector was defined as a combination of manufacturing and services industries that capture, 
transmit and display data and information electronically. Manufacturing industries need to 
fulfil the function of information processing and communication including transmission and 
display. In addition they have to use electronic processing to detect, measure and/or record 
physical phenomena or control physical process. The service industries have to enable the 
function of information processing and communication by electronic means. (OECD, 2002)
2.2.1 Characteristics of ICT industries
The products or services of ICT industries are characterized by several factors. Products are 
usually complements. Consumers are usually shopping for systems. Complementary products 
mean also that the products should be compatible. Compatible products create a coordinated 
need for standards. The utility of the products are partly derived from the number of other 
people using similar products. Other industry specific factors are switching costs and lock ins.
20
Consumers are in many cases locked in to use a specific product and face switching costs if 
an alternative product provider is recognized. (Shy, 2001)
Software business. Software business is said to be a typical informational industry in which 
theories of product pricing do not apply (Shapiro and Varían, 1999). The developing and 
coding a product usually is expensive but reproducing and distributing is very cheap. Variable 
costs are usually very small; the cost of reproducing copies is very low. Software firms are 
generally independent of the hardware producers. The versioning of the core products is a 
distinctive feature of the industry. The future of the software business is said to be Internet 
based software. Software running on Internet is not required to be compatible with operating 
systems of computers. Increased accessibility and easier installation and upgrading are other 
advantages of the Internet based system. (Shy, 2001) The revenue of the software industry is 
estimated to grow 30% per year (Rajala et al, 2001).
Content and media. In spite of international products the content and media services are 
usually national in scope targeted to local consumers. Content and media produces services in 
electronic format or reproduces information utilized in the companies. Content and media 
provider owns products sold through networks. Contents are usually culture specific.4
Communication industry. Communication industry is the fastest growing industry in a global 
scale. The rise of the sector was due to progressive deregulation of telecommunication. Other 
significant factors were advances in the wireless technology and the progression of the 
Internet. Communication industry is a typical example of network externalities i.e. customers’ 
decision to buy is dependent on the number of other users connected to the service. The 
critical mass of consumers needs to be reached before network effects increases. (Shy, 2001) 
The focus of communications industry is moving from technology to content provision. It is 
estimated that the next growth sector in the global ICT markets is content provision (Paija, 
2001).
4 Osaamislinjaus 2004. Visioista osaamistarpeisiin - huippuosaamisella menestykseen, 2000. Tekes & SET.
Helsinki.
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2.2.2 ICT in Finland
”Helsinki is the Silicon Valley of Wireless Communications”
Carly Fiorina, CEO, HP (1999)
ICT has been an engine of Finnish economy in recent years. During 1990s Finland achieved 
in a short time a status of being one of the most ICT-specialized industrialized nation in the 
world (Koski et al., 2002). Approximately 10% of the Finnish GNP comes from information 
and communications technologies. The productivity of Finland has increased since 1992 
annually by 15% and in electro-technical and telecommunications 25% (Paija and Rouvinen, 
2003). Especially communication equipment sector in Finland has been the major factor 
behind the rapid development (OECD, 2002). According to ETLA estimates Finnish ICT 
cluster value added will grow at an 8% annual growth rate over the period 2001-2015 (Paija, 
2001).
From an European point of view parts of UK, Germany, Switzerland and Italy are more 
focused on information technology (IT), while Finland (Helsinki) and Sweden (Stockholm 
















1. Classes of International Patent Classification: G06, G11 and H04.
Source: OECD, Patent database, March 2002.
As Figure 4 demonstrates, Finland has been very active in research and development in ICT 
sector from 1990 onwards.
On the other hand biotechnology and ICT do not differ that much when Nokia’s effect is 
cleared from the statistics. In the next figure is shown the patents received in US in 1985- 




Finnish patenting in US (USPTO) in 1985-1999
□
IT (Nokia excluded) 
Biotechnology
1985 86 87 88 89 90 91 92 93 94 95 96 97 98 99
Source: Luukkonen, 2004b
The Finnish ICT cluster is strongly specialized in communications technology (Paija, 2001). 
Communications technology is dominated by one company in Finland - Nokia. The cluster 
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In Figure 6 is depicted the Finnish ICT cluster. Around the key industries are those industries 
that are either supporting the cluster or somehow related to the industry. The Finnish supplier 
sector has focused on highly refined inputs while in standard components Finnish original 
equipment manufactures (OEM) rely on imports (Paija, 2001). Close vertical co-operation is 
distinctive for the cluster. Related industries produce complementary products. For example 
content providers are able to convert their products in digital format. Content providers also 
provide the packaging i.e. products are tailored to satisfy customer needs (Paija, 2001). 
Associated services are also included in the figure.
ICT cluster is under transformation because of convergence of networks, services, terminals 
and industries. Digitisation and deregulation are also shaping the face of the industry. (Paija,
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2001) Fast expanding industry complicates the definition process of the industry. Companies 
are penetrating other business areas of ICT and are also creating new ones. Vertical merger 
and acquisition (M&A) activity is an active part of cluster dynamics.
Electronics and electro-technical industry’s revenue in Finland in 2002 was 30.1 billion euros 
(Total ICT industry turnover was 46.8 billion euros in 2002). The industry includes following 
subcategories: telecommunications, consumer electronics and computers, components, 
electro-techniques, medical electronics and measurement systems and automation.5
The software industry reached in Finland 4.0 billion euros in revenues in 2002.6 The industry 
includes two sub sectors: software products and data processing services. Lassenius et al. has 
studied the software enterprises in Finland. They find out that software companies seeking 
external finance had higher growth expectations. In 2000 there were some 700 companies 
(450 in 1999) developing software in Finland. 80% of ventures were located close to 
technology centres. The average age of a software company was nine years. Almost 80% 
sold their software for 850 thousand euros or less a year. (Lassenius et al, 2001)
Content and media business in Finland reached 6.4 billion euros in 2002. The industry 
includes following sub sectors: digital media, printing and publishing, TV and radio, audio 
and video and advertising.7 Companies in the industry vary from content and service 
providers to Internet portals. Services are provided via Internet ever increasing pace and in the 
same time making classifications in the content providers industry more difficult. In Finland 
digital media production technologies are in their early stages. (Paija, 2001)
5 Unpublished information. Obtained from the database of Tekes, document number 33606.
6 Unpublished information. Obtained from the database of Tekes, document number 33606.
7 Unpublished information. Obtained from the database of Tekes, document number 33606.
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3. Theoretical framework and hypothesis
This study draws its ideas from rich sources of corporate finance. The study will focus on a 
few relevant theories from the field. In addition, theories from venture capital (VC) are 
reviewed. VC related theories are considered many times as extensions of corporate finance. 
On the other hand, venture finance is seen as a multidisciplinary field of research with various 
components from other disciplines. Venture financing is closely related to the studies of 
entrepreneurship. (Pekkanen, 2002) Entrepreneurial finance is sometimes defined as a 
subcategory of corporate finance in terms of phase of financing i.e. financing through seed 
phase to IPO (Virtanen, 1996). The description of entrepreneurial finance is very useful when 
searching for differences between public and private companies. Table 3 shows clearly how 
the private companies studied in this thesis differ from the public companies and how 
challenging the analysing of the private companies is.
Table 3.
Characteristics of entrepreneurial and corporate finance market and companies




Market • markets are 
informationally 
efficient
• transactions take 
place continuously
• efficient information 
=> risk and return 
directly related
• market inaccessible, 
unorganized and 
often invisible
• very few transaction 
during the
entrepreneurial phase; 
prices not quoted 
daily
• defies the direct 
relationship of risk 
and return
Financing • changes in overall 
financial status 
usually low
• amount and cost of 
money optimized
• capital is anonymous
• changes in financing 
volatile
• value creation in the 
long run
• milestone based to 
reduce risk
• capital earmarked





based on large 
amount of data
• Assets-in-place type 
financial ratios
important
• the most valuable 
assets are intangible 
assets and growth 
opportunities
• monitoring costs are 
related to human 
capital benefits
• valuation of the firm 
based on intuition and 
qualitative data than 
on computer 
modeling
Value added • does not include any 
other values than 
money and capital
• share price as a 
decision parameter
• financing, especially 
external equity, 
creates value added 




• commitment shown 
by equity 
participation, 
personal wealth and 
intensive effort




• main goal: create 
value in the long run




• scarce hands-on 
possibilities
• management and 
control inseparable
• ownership more 
concentrated
• hands-on practises 
common
Source: Virtanen, 1996
Next chapter begins with a brief overview on key corporate finance theories related to this 
study. The theories will be analyzed further in connection with the research problem 
presented in the introduction chapter. Theories will be analyzed also in the context of the two 
key industries studied. Based on earlier studies I will present 7 hypotheses. These hypotheses 
will be tested in the empirical part of the study.
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3.1 Agency theory
Agency theory is well known theory in finance. Agency theory describes the relationship 
between a principal (e.g. stockholder) and an agent (e.g. manager). An agent agrees - against a 
payment - to do tasks in favour for the principal. Originally the agency theory was found in 
1932 by Berle and Means, who discovered that the reduction of management’s ownership in 
some cases reduced the willingness of the management to strive for longer term profits in 
favour for short term profits. Jensen and Meckling (1976) have stated that the principal-agent 
theory is found in all organizations and in all co-operative efforts in every level of 
management.
The focus of the research has been on larger public companies. In the US the ownership of 
major corporations is widely dispersed. The lack of control has driven owners to seek ways to 
tie the management’s compensation on the value they have added. In some other countries 
like in Germany the ownership of companies is not so dispersed. Companies are owned by a 
few major institutions like banks and they can review the situation of the companies more like 
the company insiders do (Brealey and Myers, 2000). Situation in Finland resembles the 
situation in Germany but basic questions of agency problems are still valid also in an 
European context. The two key problems in agency relationships are agency problem and 
problem of risk sharing. The former is composed of two categories: (1) Agency problems that 
arises from conflicts between principal and agent on goals, (2) problems on verifying the 
doings of an agent in a setting when close follow up is difficult or it is very expensive. The 
latter problem consists of a situation where the principal and agent have different attitudes 
towards risk. (Eisenhardt, 1989) From an entrepreneurial point of view conflicts could 
consists of lack of congruence in strategies, research and projects that are highly rewarding 
for the entrepreneur but offers low returns for the venture capitalist (Gompers, 1995). In the 
field of high technology, which is based on latest scientific knowledge there is a possibility 
that the entrepreneur has self-serving goals like scientific reputation. In some cases the 
research done is too far from being commercially applicable, yet very interesting from a 
scientific point of view. Agency costs are easily recognized when for example biotechnology 
companies are in question. Venture capitalist might have difficulties to understand whether
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the company is doing the right things e.g. not continuing the basic research from university 
under VC finance.
One underlying reason of agency costs is asymmetric information i.e. the different level of 
information between the management and the investors. Investors are not usually involved in 
the daily activities of the company. Of course one of the most crucial phases is the initial 
investment of the investor. Before investing the investor incur direct and indirect costs e.g. in 
form of due diligence costs. Also post-investment phase has agency costs. The entrepreneur 
might take too risky projects or be satisfied with a low return projects. The investor has 
normally an exit strategy that requires certain milestones to be achieved and due to agent’s 
moral hazard (lack of effort) the goals could be endangered. Adverse selection problem 
means in VC context for example that only the least desirable entrepreneurs offer their 
business ideas to investors. This could result from a situation where investors find it difficult 
to recognize the potential investment targets from the least desirable (Gompers and Lemer, 
1999). For example a scientist could claim to have experience in a certain scientific field and 
the investor cannot verify the claims (Eisenhardt, 1989). Leland and Pyle (1977) were among 
the first to propose that even positive net present value projects could be hindered by 
asymmetric information. The problems are most difficult in the early stages of company 
development. It is suggested that asymmetric information problem could be at least partly 
above firm-specific variables. In industries with unproven future prospects, changes in 
asymmetric information surrounding individual firms might be positively correlated. This was 
true in biotechnology in the US in the 1980s and in electronic commerce in the 1990s. (Lemer 
et al., 2003) In other words, an evaluation of a company could change due to new information 
concerning another company in the industry. High opacity of the firms is one reason why 
companies might have pressures for self-selection i.e. firms with high growth prospects and 
limited financial information might choose for high quality disclosure e.g. prestigious auditors 
(Hyytinen and Pajarinen, 2002)
According to Gompers (1995) the structure of financing would be irrelevant if the agency 
costs and asymmetric information did not exist. Investors would allocate money quite freely 
and entrepreneurs would feel free to use it as they prefer.
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3.2 Intangible capital
It is widely accepted that research and development (R&D) investments contribute positively 
to economic growth. Since the studies of Schumpeter (1942) an impressive amount of 
literature has been accumulated on the subject. Lately there have been more and more 
questions concerning how the market value of young technology firms is determined. It is 
evident that the determinants of growth opportunities for emerging firms need to be studied. 
ICT and biotechnology firms are different from the brick-and-mortar enterprises in many 
ways. For example, they generate negative earnings and may have no production utilities for 
several years. However, only few academic studies have attempted to measure or explain their 
market capitalization (Gamer et al., 2002).
One used hypothesis is that firms with higher intensity of R&D investments relative to the 
industry averages are more likely to have higher market value of growth opportunities. The 
reason behind this is that they are expected to win the race to innovate. Very often in the 
financial literature Tobin's q i.e. the market value of the firm divided by its replacement value 
is used as a proxy for the market value of the firm’s growth opportunities. For private 
companies the market value is difficult to define and so the use of Tobin’s q is less adequate. 
The research of Gamer et al. (2002) showed that the larger the relative R&D investment, the 
greater is the market value of the firm. The results were in line with their theoretical 
prediction of firms with higher speed of innovation being higher valued in the market. Firms 
are highly motivated to carry out R&D because they are after for monopoly profits that can be 
achieved when a patent is accepted.
The study of Darby and Zucker (2002) argued that the biotech firms with the deepest science 
base will be the most successful in financial rounds and in the same time achieve sufficient 
R&D success. They also argued that more funding would be directed to firms where the star 
scientists were involved in base level science and not only authorizing their name to be used 
in a scientific advisory board. Proxies for a firm’s science base were the number of articles 
written by star scientists, granted patents and whether or not a firm uses rDNA technology.
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They found that strong science base increased the likelihood of a company to go public. They 
also interpreted the results so that the involvement of a star scientist in a company is more 
likely to bring venture capital financing.
3.3 Capital structure
There are many studies on capital structure. The modem debate on the capital structure choice 
originates from the theory of capital structure irrelevancy proposed by Modigliani and Miller 
in 1958. The theory suggests that the choice of capital structure should not matter. In perfect 
markets changes in capital structure do not affect company value as long as the total cash flow 
generated by the firm’s assets is unchanged. The value of the whole should be left intact 
irrespective of the fact how it is sliced. (Modigliani and Miller, 1958) In their partial 
equilibrium analysis both companies and individuals can lend and borrow without limits. The 
model is a simplification, for instance the effects of taxes, agency costs, financial distress and 
asymmetric information are not included.
According to Harris and Raviv (1991) the capital structure theories can be divided into five 
categories. Tax-based theories emphasize the importance of interest tax shields. The second 
category includes the agency cost considerations concentrating on a) principal-agent conflicts 
or b) conflicts between equity and debt holders. The third approach attempts to find a relation 
between a firm’s capital structure and the input or output markets. Forth approach is 
asymmetric information category that deals with signalling effects in the capital markets and 
the effects of adverse selection on it. Finally, the fifth group concentrates on issues related to 
corporate control.
Capital structure decisions have been explained in small business studies by the pecking order 
hypothesis (Virtanen, 1996). Pecking order hypothesis suggest that firms prefer internal 
financing. If external finance is needed, firms prefer debt and hybrid securities before equity. 
This theory explains the debt ratio within industry because less profitable firms have to 
borrow in order to keep up with the growth of their industries. It is less successful when 
explaining interindustry differences. For example debt ratios are usually low in high 
technology and high growth industries even when external finance is needed. (Brealey and
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Myers, 2000) Brealey and Myers remark that companies facing significant costs of financial 
distress might not follow the pecking order hypothesis.
A partially reversed pecking order theory implies that VCs have invested before banks and 
other financial institutions (Hyytinen and Pajarinen, 2002). Firms resort to outside equity 
finance before they can obtain significant amount of debt. In Finland especially biotechnology 
firms are heavily financed by external equity. Also the trade-off theory of capital structure 
states that the target debt ratio varies from company to company and industry to industry. 
There exists a trade-off between the interest tax shields and the costs of financial distress. 
Unprofitable companies with intangible assets ought to rely on external equity financing and 
more mature companies with tangible assets and taxable income should have high debt ratio 
in order to utilize tax shields. (Brealey and Myer, 2000)
3.4 Company growth
Generally, it can be said that the growth of the firm is the expansion of its activity8. However, 
there is no single, generally accepted measure of firm growth. It is usually measured by the 
number of employees, the amount of capacity, the amount of total assets, the annual sales, 
sales margin, operating margin or market share. All these measures are surrogates of the 
activity of firm. (Kanto and Tuovila, 1987)
The concept of gazelle was introduced by David Birch in 1979. A gazelle is a small or 
medium-sized company with an explosive potential and an ability to sustain rapid growth. A 
more detailed definition states that gazelles are firms with at least 20% sales growth every 
year. The starting level of sales has normally been at least $ 100,000. (Gregory, 1998; Case, 
1996) As a by-product of his research Birch found that small firms created 82% of new jobs. 
This was in sharp contrast with earlier studies. Gazelles accounted for more than 70% of the 
growth in the US between 1992 and 1996. Of the entire firm population gazelles represented 
only about 3%. They were found in all industries but only 1.8% of gazelles were found in 
high-tech industries. (Birch et al. 1997) An OECD study has found that less than 20% of new 
firms achieve rapid growth. The majority of firms maintain their initial turnover, number of
8 Often called the size of the firm
33
jobs and market share or downsize. In contrast to Birch’s et al. findings they found that high- 
growth firms operated in the medium-to-high and high-tech sectors and in industries 
dominated by large companies. In addition, exports had a positive correlation with growth. 
(Julien et al., 1998) In a Finnish study of gazelles, Ere Vakkilainen (1999) found that in 
general high-tech industries had high-growth firms. The time span of the study was 1994- 
1997, which includes very good years for Finnish ICT-sector.
Not all studies support the view that high technology firms are growth oriented. For example 
Kamshad and Hay (1996) found that the management goal in the new technology-based firms 
is profitability instead of growth.
3.5 The influence of a venture capitalist on company growth
“You can compare receiving the venture capital investment as a situation where you 
place a turbo engine in an ordinary machine. This will make the increase of the speed of 
revolution possible. In agrarian terms, a venture capital investment is like fertilizer: it 
costs something, but creates faster growth when added.”9 - One entrepreneur view of 
venture capital finance.
From the days of Berle and Means (1932) a lot of attention has been put on the company 
owner’s ability to look after and influence the actions of executives. The mainstream of the 
research has focused on large public companies. However, there are studies were the 
corporate governance problem is said to apply also to smaller companies with less dispersion 
in ownership (Eisenhardt, 1989).
Governance measures are possible to define in many ways. One way is to divide the 
governance measures in two groups: active and passive. Passive measures are typically 
compensation schemes, contractual covenants and strict reporting requirements. Active 
measures require frequent involvement from the investor. (Pekkanen, 2002) It is very 
common that in spite of the governance measure used, venture capitalist sit on the boards of 
directors. An active role could for example include following activities: help recruit key
9 Virtanen, 1996.
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personnel, negotiate with suppliers and customers, aid in strategy formulation, raise additional 
capital and help in M&A activity (Pekkanen, 2002).
In a number of studies of venture capital involvement and value added, the results tend to be 
merely descriptive and atheoretical (Sapienza, 1996). Gorman and Sahlman (1989) found that 
the level of investor involvement varies markedly. For example Rosenstein (1988) shows that 
venture capital investors are more involved than outside shareholders in public companies. 
MacMillan et al. (1988) state that the level of involvement is determined by a personal choice. 
MacMillan et al. claims that active investors feel that they have managed as well or bad as 
those who are passive. Ehrlich et al. (1994) found that there is no difference between private 
investors and venture capitalists in activities they are involved.
Virtanen (1996) has studied the Finnish venture capital environment. He states that venture 
capitalists add value in small economies by assisting in the internationalization process of 
companies. Growth opportunities in small countries require foreign purchasing power. 
Virtanen states that companies seek venture capital to increase their credibility. Other forms 
of value added in Virtanen’s research are networks, financial consultancy, general 
management, collateral offerings and acting as a sounding board.
Attitudes of entrepreneur and venture capitalists towards venture capital decision making 
process might diverge. For venture capitalist an investment decision may be a portfolio 
selection problem although studies support more specialisation than traditional portfolio 
selection problem (Norton and Tenenbaum, 1993). For an entrepreneur the situation might be 
more like a dynamic growth problem. Virtanen (1996) refers to an “all-or-nothing bet” in 
entrepreneur’s case and in VCs point of view there are several bets. In his case study some of 
the entrepreneurs commented the VC involvement by saying that the VC investment made 
possible riskier projects and paved the way for higher growth. Virtanen states that 
theoretically a firm chooses a venture capitalist only if 1) the overall growth of the expected 
market value of the firm during the investment period is larger than it would be without VC 
investment (venture capital advantage) 2) the firm ex ante presupposes to be able to utilize 
some of it. The venture capital advantage is calculated as a cumulative sum of net cash flows 
over the entire investment period. However, in spite of the growth opportunities included in
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the VC investment, it is argued that since the venture capital is very expensive10, why the 
most promising companies should resort to it. In many cases the involvement of a VC is 
justified by getting something else than just money (Timmons, 1994).
The asymmetry of the information between the entrepreneur and investor might lead to a 
situation were the agent tries to window-dress or exaggerate the success or potential success 
of projects (Leland and Pyle, 1977). High growth estimations of the companies might indicate 
also something else than CEOs pressure to communicate only up side view of the company to 
the investors. Venture capitalist could be seen as informed agents that have the ability to 
identify promising start-ups. Baum and Silverman (2003) call the phenomenon as the picking 
winner’s theory. Venture capitalists could be seen also as building winners. Baum and 
Silverman argue that the coach aspect could be disentangled from picking winners theory by 
analyzing differences in revenue estimations. If the company estimations are low, the venture 
capitalist is still building the winner. The problem with this kind of research is that both 
aspects are usually positively associated with start-ups’ future performance. The difficulty to 
disentangle these two effects is probably one of the most obvious reasons why the research 
literature is scarce.
Venture capitalists are after high returns since the risk included in the start-ups is very high. 
They are interested in possible success stories with high growth opportunities. Do the 
companies forecast higher growth prospects when venture financing involved? Is the possible 
turbo-effect seen from the project specific turnover estimations? Based on the literature above 
I put forward the first hypothesis:
HI: The revenue estimations of the companies with venture capital involvement are higher 
than in companies without VC investments.
Virtanen (1996) stated that growth opportunities in Finland require internationalization. The 
second hypothesis is following:
H2: The higher the exports or the share of exports of company turnover, the higher the growth 
prospects are.
10 rf. pecking order theory earlier on in Chapter 3.3.
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3.6 The solidity against company growth
Generally it is assumed that the optimal capital structures are closely related to the growth 
potential of the firms. Capital structures of firms are also related to the size of the firm and to 
the industry characteristics. (Chen, 2002) Harris and Ravivin (1991) argue that high solidity, 
that is low leverage, implies high growth rates. The studies they reviewed generally agreed on 
the negative relation between growth and leverage. The inverse relation between leverage 
and growth is that growth opportunities usually are intangible assets that have low or zero 
collateral value and due to this firms have to rely on lower leverage (Tiiman and Wessels, 
1988). Many times high tech firms can be credible issuers of common stock because their 
bankruptcy of financial distress would be extremely costly (Brealey and Myers, 2000). 
Growth firms lack also taxable earnings needed to make use of interest tax shields.
Building on the argument above, leverage is negatively correlated with high growth rates, and 
positively correlated with low growth rates. Thus, third formulation of hypothesis is 
following:
H3: The higher the solidity of the company, the higher its growth prospects are
The results should imply that the growth opportunities may influence the capital structure.
3.7 R&D as a growth factor
In Chapter 3.2 of intangible assets few important aspects of positive impacts of R&D 
investments on company growth was discussed. The evidence from Finland (Hermans and 
Tahvanainen, 2002) and abroad (Gamer et al., 2002) indicate that intangibles should be taken 
seriously. To illustrate the role of intangibles in economy one need to only remind that in US 
e.g. in 2000 private US firms invested at least $ trillion in intangibles. (Nakamura, 2003) 
Bearing in mind the arguments for the relevance of R&D expenditure I bring forward the 
forth hypothesis of R&D investments:
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H4: The higher the annual R&D costs or R&D intensity, the higher the company growth 
prospects
3.8 Hot market condition
Darby and Zucker (2002) studied the factors influencing biotechnology companies going 
public. One of the independent variables explaining the increased likelihood of biotech 
company initial public offering was so called “hot market” condition indicated by prior high 
returns. They found out also that a prior hot market increased the expected amount of money 
that the firm will raise if going public. I will use the idea of hot market condition in 
explaining high growth prospects. In this study the hot market condition is in effect if 
company’s actual sales have increased. Is prior hot market related to CEOs view on future 
growth prospects?
H5: The higher the actual revenue increase, the higher the growth prospects in the future
This formulation is invalid for many biotech companies because many of the companies do 
not have revenues. A special group are gazelle companies. The hot market condition is 
presupposed to be strongly operating when a company is considered to be a gazelle company 
i.e. the company revenue has increased 20% or more per year for three years (2000, 2001, 
2002) or if for some reason data was available only for a shorter period (company established 
later on etc.) the longest period possible between 1999-2002 is utilized. The starting level of 
sales has to been at least 100,000 €. The study will also shed light to the controversy whether 
high tech firms are really growth oriented or not.
3.9 Future research and development investments
Previously, arguments for the including of past R&D costs as a variable explaining company 
growth were justified. If past R&D costs are relevant, then should also future R&D 
investment be relevant. As a future R&D investment, the study will use as a proxy the project 
specific estimate of R&D costs. In fact, it is more than a proxy in a study context because it
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states the R&D investment needed to achieve the project specific target turnover estimate 
used in this study as a dependent variable.
H6: The higher the estimated future R&D expenses of the project or the higher the future 
R&D project investments divided by company balance, the higher the growth estimate of the 
firm
3.10 Company age
Are younger companies eager to grow faster than elder counterparts? Earlier research 
supports the notion that from the two industries under examination, the biotech business in 
Finland is in a phase were younger companies are bold in their future views. Hermans and 
Luukkonen (2002) found that the highest anticipated growth rates of biotech firms were from 
the youngest age group (founded 1997-2001). However, also in general the biotech field aims 
to grow faster than the economy as a whole while even the oldest companies (founded before 
1991) anticipate growing 7% annually.
H7: The younger the company, the higher its growth prospects
4. Methodology
In this chapter the methods of collecting and analyzing the data of company growth 
estimations is presented. The chapter starts with an overall presentation of the data, which will 
serve as background information and it should give a reasonable understanding of its quality. 
I show descriptive statistics of the data to convey a good understanding on the nature of the 
firms and their projects in the sample. I will also describe the interviews conducted during the 
research. Also the data of the latter part of the study is introduced. After that I will present and 
explain the dependent variable and the multitude independent variables used to test the 
hypotheses. Finally, I present the regression models used in the study.
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4.1 Description of the data
The main part of the data is collected from the database of the National Technology Agency 
of Finland (Tekes). Tekes is the most important public financier of business R&D in Finland. 
The agency promotes the competitiveness of Finnish industry and the service sector via 
technology. Tekes provides funding and expertise also to universities, research institutes and 
academic institutions.
The data obtained from Tekes was semi-structured from the study perspective. The data 
consists of revenue expectations of 256 ICT and 80 biotechnology projects. The time period 
over which the BIO data is collected is 1.7.2002 - 31.12.2003 and for ICT data 1.1.2003 — 
31.12.2003. The revenue estimations are project based estimations since Tekes is interested in 
collecting data of the projects they are partly financing. Growth estimations are made by the 
applicants but there is also a reality check done by the experts in Tekes. The applicant 
company has to estimate not also the revenues in question but also the timing of revenues i.e. 
the year when the project outcome (product, service) will be on the market plus two 
subsequent years and the target year when revenues are highest.
The data includes also basic company financial information, e.g. company revenues, earnings 
before interest and taxes (EBIT), earnings, exports, R&D expenses, number of employees, 
share capital, shareholders equity, total assets, quick ratio and the ownership share of a large 
company. Semi-structured information is found from the project appraisal memorandums. For 
example, the involvement of venture capital investors is possible to find out from these files. 
Likewise, the ownership structure is in many cases described on these files.
The sample of Finnish high technology companies consists of two sub-samples - ICT and 
biotechnology companies. The two sub-samples will be reviewed separately but the sample is 
analyzed also as ALL DATA. Differences between the two sub-samples might originate from 
the sector specific factors described next or from the differences of independent variables 
explaining revenue estimations in each sub-sample.
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ICT and biotechnology companies were selected because they are truly high tech industries 
and both are seen as very prominent from a Finnish perspective. Especially ICT is already 
proved its potential. Biotechnology is still in its infancy but the activity in the industry is at 
the moment (2004) remarkable in Finland. Public R&D investments in biotechnology are 
notable and the industry is one of the main activity areas of Tekes. Both industries are quite 
young and they have sprouted many young high tech companies with high growth potentials.
The data used in the latter part of the study for comparing the actual and estimated 
development of turnover in both industries is described in the findings (Chapter 5.3) section 
but some information of the data is given already here. The ICT sample (N=75) is from a 
follow-up data of Tekes for the projects which ended in 2000. In spring 2003 1827 
questionnaires was sent. The response rate was quite high (70.2%). The aim of the follow-up 
studies is to have information on how the projects have developed after the companies have 
submitted the final report to Tekes. The ICT sample includes the received responses from 
projects ended in 2000. In biotechnology, the history data is collected from those companies 
that were included in the BIO data and who had projects accepted for Tekes funding in 1997- 
1999.
4.2 Description of the samples
The whole data included 293 companies. Out of the two sub samples the ICT group is the 
largest comprising 240 companies (81.9%). The biotech sample size is 53 companies (18.1%). 
The sample of biotech companies is bit smaller than for example in the recent research 
published by ETLA (N=84) (Hermans, 2004a). From the ETLA database Raine Hermans’ 
study focuses on pharmaceutical companies and companies whose customers are or will be 
pharmaceuticals (N=42) and to the explanation of their business potential as companies. 
According to ETLA studies there are approximately 140 companies in biotechnology in 
Finland and in ICT 4000-5000 (Luukkonen, 2004b). 140 companies in biotechnology include 
also large companies. In this respect the SME biotech sample in this study is quite 
representative, since some of the 140 are also inactive due to various reasons e.g. they are 
established in order to safe-guard accepted patents or they have not been able to raise 
sufficiently money for starting business. As the focus of this study is not a company level, the
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samples consists more cases than there is companies. In biotech many companies have 
applied funding for different projects and this is the reason for higher total sample (80 
projects for 53 firms). The ICT sample is a smaller set compared to the whole population, but 
for statistical purposes it has enough power. In fact the sample could be overly sensitive but in 
the regressions from the data only 206 cases are included listwise due to missing data 
problems. In biotech the number of projects accepted listwise in the regressions is 65-70 
(depending on the regression model used) out of 80 projects included in the data. The ICT 
companies had usually only one project during the period. The sample period for biotech 
companies is half a year longer than for ICT sample which could explain at least partly the 
higher number of projects per company in BIO data. At this point it is worth noting that the 
projects included are all project applications from the sample periods i.e. also rejected projects 
are included in order to at least partly avoid the obvious selection bias problem in the 
samples.
In the next table (Table 4) is gathered the key descriptive statistics analyzed in the following 
pages. The company distribution by region in Table 4 reflects relatively well the overall 
geographical distribution of biotech companies in Finland (Luukkonen, 2004a). Finland 
Proper (17 companies) and in it especially Turku (15) has a major share alongside with 
Uusimaa (16). Far behind come Northern Savonia (6), Northern Ostrobothnia (5) and 
Pirkanmaa (4). Compared to the overall distribution presented by Luukkonen, it seems that 
Uusimaa is underrepresented in this data. In Luukkonen’s description out of the 140 
companies 47 comes from Helsinki and only 38 from Turku region.
Table 4.
The description of the sample
The table show few key descriptive statistics of the data. The number of firms, projects, distribution by region, 
age structure, company size, and the existence of venture capitalist lays the foundation of the study. R&D 
intensity, company solidity, export intensity, turnover and earnings before interest and taxes in 2001 and 2002 
give a portrait of the financial status of the companies.
BIO ICT ALL DATA
Number of firms 53 240 293
Number of projects 80 256 336
Distribution by region
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South Karelia 0.0% 1.7% 1.4%
Southern Ostrobothnia 3.8% 0.8% 1.4%
Southern Savonia 0.0% 0.8% 0.7%
Tavastia Proper 3.8% 0.4% 1.0%
Eastern Uusimaa 0.0% 0.4% 0.3%
Kainuu 0.0% 0.8% 0.7%
Central Ostrobothnia 0.0% 0.4% 0.3%
Central Finland 1.9% 2.9% 2.7%
Lapland 0.0% 0.4% 0.3%
Pirkanmaa 7.5% 7.1% 7.2%
Ostrobothnia 0.0% 0.8% 0.7%
North Karelia 0.0% 1.3% 1.0%
Northern Ostrobothnia 9.4% 14.6% 13.7%
Northern Savonia 11.3% 2.9% 4.4%
Päijänne Tavastia 0.0% 2.1% 1.7%
Satakunta 0.0% 2.9% 2.4%
Uusimaa 30.2% 55.4% 50.9%
Finland Proper 32.1% 4.2% 9.2%
Age Structure
0-4 37.7% 50.4% 48.1%
5-8 32.1% 16.7% 19.5%
9-24 28.3% 30.8% 30.4%
>=25 1.9% 2.1% 2.0%
Company size
0-4 45.3% 29.2% 32.1%
5-9 13.2% 23.3% 21.5%
10-19 17.0% 20.8% 20.1%
20-49 17.0% 20.0% 19.5%
50-249 7.5% 6.3% 6.5%
250-499 0.0% 0.4% 0.3%
Venture capitalist
No venture capitalist 39.6% 65.0% 60.4%
Venture capitalist 60.4% 35.0% 39.6%
2002 BIO N ICT N ALLDATA N
Mean R&D 
intensity
68.9% 35 48.3% 187 51.6% 222
Median R&D 15.5% 35 32.3% 187 32.3% 222
intensity
Mean solidity 51.8% 35 41.1% 197 42.7% 232
Median solidity 53.3% 35 43.8% 197 47.3% 232
Mean export 24.5% 35 16.3% 189 17.6% 224
43
intensity
Median export 0.0% 35 0.0% 189 0.0% 224
intensity
Mean turnover, € 559,432 39 1,595,818 198 1,425,274 237
Median turnover,€ 70,000 39 326,000 198 303,000 237
Mean earnings,€ -1,745,402 36 -480,981 198 -675,508 234
Median earnings,€ -107,500 36 -21,000 198 -36,000 234
2001 BIO N ICT N ALLDATA N
Mean R&D 
intensity
42.5% 45 48.2% 168 47.0% 213
Median R&D 30.0% 45 25.7% 168 26.7% 213
intensity
Mean solidity 51.9% 45 39.9% 171 42.4% 216
Median solidity 66.0% 45 49.3% 171 52.7% 216
Mean export 32.1% 33 18.5% 156 20.9% 189
intensity
Median export 9.7% 33 0.0% 156 0.0% 189
intensity
Mean turnover, € 670,743 46 1,496,264 174 1,323,655 220
Median turnover,€ 52,500 46 341,000 174 252,500 220
Mean earnings,€ -1,030,993 46 -396,105 173 -529,460 219
Median earnings,€ -35,000 46 -3000 173 -5000 219
The ICT sample is heavily Uusimaa driven; 133 companies out of 240 (55.4%) originates 
from Uusimaa; Helsinki (79) and Espoo (47) leading the way. Other notable regions are 
Northern Ostrobothnia (35), Pirkanmaa (17) and Finland Proper (10). From Northern 
Ostrobothnia the Oulu-region (27) is according to expectations well represented since it has 
strong ICT sector in general. Regions without projects are Kymenlaakso and Åland Islands. 
Åland Islands is an autonomous province of Finland and companies from this province are not 
eligible for funding from Tekes.
Biotech companies are relatively young in the sample. 37.7% are 0-4 years old and 32.1% 5-8 
years old. Thus approximately 70% of the biotech companies are established 1996 or later. 
Only one company is more than 25 years old. Similar age structure is also in ICT companies; 
half of the companies are 0-4 years old. The major part of the companies being very young is 
partly explained by the boom in ICT in the late 90’s and early 2000. However, it is also
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explained by the activities of Tekes in 2003. Tekes increased its funding for start-ups and 
young companies in 2003 in order to strengthen the growth of high-tech companies from the 
beginning.
Company size is also measured". Biotech companies are small almost entirely. Only 4 
companies (7.55%) are medium-sized companies. 45.3% of the companies had 4 or less 
employees. 75.5% of the companies employ less than 20 persons. In ICT the cumulative 
percentage for firms employing less than 20 persons is nearly the same but in general the 
distribution by size is more evenly distributed. Medium-sized companies are better 
represented in the ICT group.
Venture capital involvement is quite frequent in biotech companies since roughly 60% has 
VC investments. In the ICT sample 35% has venture capital. Biotech as a business is typically 
capital intensive and by default involves capital investments. Foreign VC involvement is also 
studied and in both groups it is quite marginal11 2. These results support the views that foreign 
VC is underrepresented in Finnish high-tech companies. Finnish VC’s portfolio companies in 
all data are centred to Uusimaa (52.6%) before Finland Proper (12.9%) and Northern 
Ostrobothnia (10.3 %). Major part of the investors is in very young companies, 0-4 years 
(44%). From biotech companies Finland Proper has best caught the eye of VC’s having 
43.8% of investors. In ICT VCs are strongly concentrated in Uusimaa (60.7%), the second 
being Northern Ostrobothnia with 11.9% of investors.
Both samples have very R&D-intensive firms13. The mean R&D-intensity in 2001 for biotech 
firms is 42.5% and for ICT firms 48.3%. In 2002 the mean R&D-intensity for biotech firms is 
as high as 69.0% and for ICT 48.3%. Especially the results for year 2002 are somewhat 
expected because some of the biotech firms have extremely high R&D-costs resulting to 
higher mean figure. The median intensity is nearly the same for both groups in 2001. In 2002 
the median is higher for ICT companies.
11 Small company = less than 50 employees. Medium-sized company = less than 250 employees.
12 The percentage share of foreign venture capital investments from the ALL DATA is 5-7 %. However, there 
might be some measurement error due to problems of defining foreign VC. In spite of that I believe that the level 
is right.
13 R&D-intensity = R&D costs in 2002 or 2001 divided by the balance sheet of that year.
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The solidity of biotech firms for example in 2002 (mean 51.9%) is higher than in ICT (39.9%) 
firms. This reflects the fact that in biotech firms VC’s are more actively engaged. Also in 
general biotech firms cannot raise traditional loans from banks due to lack of collaterals. 
However, these results indicate also that strong solidity is needed in ICT. In some cases it also 
means that company has been profitable and the balance sheet is stronger due to accumulated 
earnings.
Export intensity is highest in the biotech sample in both years. However, the median value for 
both groups in 2002 is 0 because major part of the companies is in the early stage of company 
life cycle. It is clearly seen that out of those companies exporting, the biotech industry is 
straight from the beginning aiming for international markets.
Due to young age of companies, company revenues and earnings data for longer periods is 
only possible to achieve for smaller set of companies. The mean revenue for biotech sample 
companies in 2001 is 670,743 €, and median 52,500 €. For example 14 companies out of 39 
have zero revenue in 2002. Mean EBIT in 2001 is -1,030,993 € (median -35,000 €). The trend 
of higher bum rates of some biotech companies is seen from the EBIT values through years 
1999-2002. The mean revenue for ICT group companies in 2001 is 1,496,264 € (median 
341,000 €) and mean EBIT -396,105 € (median -3000 €). This simple description shows that 
ICT companies are clearly in the business but are unprofitable. One reason for making losses 
is probably their high R&D-intensity showed earlier. In both groups companies are young and 
in their early phase of development and in the same time developing their product portfolios 
through R&D. The median and mean turnover figures are higher in 1999 than they are in the 
last two years. A decreasing trend is noticeable in the mean and median figures of earnings 
before interest and taxes from 1999 onwards which would at least partly reflect the overall 
trend in the ICT before and after the Internet bubble without forgetting the overall economic 
downturn in Finland.
The data for project-based target turnover estimations include 350 projects for 293 
companies. Turnover estimations of 14 projects are not available because the nature of the 
projects did not allow turnover estimations for different reasons. 336 projects with turnover 
estimations include 256 ICT-projects and 80 biotech projects. The mean target turnover 
estimation for biotech projects is 51 million euros compared to 10 million euros for ICT 
projects. 5% trimmed mean for biotech is 31 million euros and for ICT 6,1 million euros.
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Median figures are little lower - 10 million euros for biotech and 3 million euros for ICT. 
Some ICT and biotech companies have very high turnover estimations reflected in the mean 
figures. Target estimations reflect also the difference between ICT and biotech expectation 
environment. The difference comes even clearer when comparing the turnover target years 
presented in Figure 7. The target turnover revenues for the bio companies are much further 
away than the estimates of the ICT companies.
Figure 7.
Target turnover estimations
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The data included also turnover estimations for market entry plus two subsequent years 
followed by the target year. In the Figure 8 the turnover figures for the years between market 
entry years and target year have been interpolated linearly. For biotech projects also turnover 
estimations without interpolation is shown in order to show a view where the time span 
between market entry years and target year is not expected to yield sales. Patent protection 
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In the figure is described the turnover expectations of ICT and BIO firms with different scenarios. Interpolation 
means in this context that years between market entry and the target year are interpolated linearly. For BIO data 
also turnover estimations without interpolation is included to show a view where the time span between market 
entry years and target year is not expected to yield sales. For BIO enterprises patent protection after target year is 
supposed to last until the end of our research period.
It is easily seen how different the projects are when timing and level of expected sales is 
considered. The biotech projects are supposed to yield significant sales after 2007 and the first 
peak should be in 2010 with interpolation. Even without interpolation the sales in 2007 would 
be above 500 million euros and the first peak would be in 2010. After 2010 there will be also 
target years with significant sales leading to 3,5 billion sales in 2019 all projects included. 
The sales peak for ICT companies is already in 2006, which reflects the product development 
period of two to three years in software development. For ICT projects no sales extension 
period after target year is extrapolated because product life cycle is quite short in ICT. This is 
why the target turnover graph decreases so drastically after the target year for ICT companies. 
Generally, it is very likely that no failure probabilities have been considered from company 
side because the turnover levels are so high. It is clear that many projects will not succeed.
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The failure probabilities of projects would be interesting to study. By determining the failure 
rate of the projects it would be possible to create a more reasonable picture of the projects.
Most common market entry year for a biotech company project is 2004 and 2005. The market 
entries normally mean licensing fees and milestone payments. In many cases the target year 
revenue estimation is not direct sales revenues but royalties from another company which is 
expected to take the company R&D-product to the markets. The most common target year for 
biotech projects is 2010 (27.5%). For ICT projects the most common market entry years are 
2003 and 2004. The most common target year is 2006 (37.8%) followed by 2007 (22.0%) and 
2005 (21.2%)
4.3 Expert interviews
To gain qualitative information on company revenue estimations, I discuss the results with 
Tekes experts of ICT and biotechnology. The primary goal is to achieve in-depth knowledge 
of the dynamics behind company growth estimations. The objective is to gain understanding 
of the interactions behind the data but also to get deeper understanding of the findings and 
also to challenge them against industry expert’s views. Expert interviews are not written out 
in the study as an independent chapter. The primary goal of the discussions is to contemplate 
and refine the analysis.
4.4 The market analyses behind the growth estimations - a qualitative approach
Another attempt to get behind the figures is done by analyzing the qualitative information 
provided by the companies themselves when applying funding from Tekes. The most 
important part is the applicants’ analyses of the business potential of the project. The 
information received from the applications is viewed against the turnover estimations given 
by the companies. Similarly to expert interviews, the results of the qualitative approach are 
used in the study only to contemplate and refine the analysis not as an independent part of the 
study itself. Limited space and the focus of the study affected also how the interviews and the 
qualitative part were arranged.
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4.5 Measures for testing hypotheses
In the following sections I will present the variables, the dependent variable and several 
independent and control variables. The regression tests are introduced in Chapter 4.6.
4.5.1 Estimated target turnover
In the Chapters 3.5-3.10 systematic factors behind company growth has been discussed. There 
is many ways to determine company growth. Turnover development is often used measure. In 
this study, the focus is more specific. Instead of aggregate company turnover figures, the 
measure is project-specific turnover growth estimates. The dependent variable is the estimated 
target turnover for a R&D project (summary statistics in Table 5). Companies have estimated 
themselves a target turnover for their R&D project when applying funding from Tekes. The 
basic idea of the regression is to find relevant factors behind company growth estimations.
Table 5.
Summary Statistics of Target Turnover for Model 1 and Model 2
The table presents the means (Mean) and standard errors (Std. error) for the dependent variable target turnover. 
Target turnover is the estimated turnover of a R&D project. Summaries of a target turnover in both models have 
been included in the table.
Model 1 Mean Std. error N
BIO Target turnover 54,427,941.08 16,181,965.53 65
ICT Target turnover 9,292,072.33 1,467,364.35 206
ALL DATA 
Model 2
Target turnover 20,118,018.71 4,184,008.02 271
BIO Target turnover 47,110,916.71 13,644,859.89 70
ICT Target turnover 9,495,883.01 1,469,656.79 206
ALL DATA Target turnover 19,035,927.79 3,744,816.62 276
The following variables have been formed based on earlier scientific research dealt in Chapter 
3.
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4.5.2 Independent and control variables
The study included various independent variables to explain target turnover figures. The 
regression models include 5-6 independent variables depending on the model and one control 
variable. The summary statistics of the variables are presented in the Tables 6-7.
R&D intensity and R&D costs
Company R&D investments relative to company balance (R&D intensity) is considered as an 
input factor behind company growth. Normally the intensity is measured by dividing the 
reported yearly R&D costs by total costs. The data did not include total costs of companies. 
The balance of a company is a closest proxy at hand. In the section 4.5 I will present the 
regression models but it is worth noting also here that two models were formed from the data. 
The first model used proportional data like R&D-intensity and the second was formed from 
absolute figures. Thus, in the other model yearly R&D costs were regressed against target 
turnover. R&D costs are from years 2001 or 2002 depending on the availability of 
information. The majority of the data was from year 2002.
Solidity
The inverse relation between leverage and high tech company growth with risky projects is 
quite generally accepted concept. Solidity is measured by dividing capital and reserves by 
balance sheet. The figures are also in this case mainly from 2002 but in some cases date back 




Summary statistics of the Independent and Control Variables in Model 1
The table show the means (Means) and standard error (Std error) for the independent and control variables. 
Solidity = capital and reserves / balance sheet; Export intensity = exports / turnover; Venture capitalist = whether 
the company has venture capitalist involved (0 = no, 1= yes); Future R&D investments related to company 
balance = Project related future R&D investment / balance sheet; Hot market condition = revenue increase 1999- 
2002 or in case of no data from that period - longest period possible; Company age = age of company in year 
2004; R&D intensity = yearly reported R&D costs / balance sheet.
Mean Std error N
BIO
Solidity 51.19 3.05 65
Export intensity 21.33 4.33 65
Venture capitalist 0.74 0.05 65
Future R&D investments
related to company balance 37.80 36.30 65
Hot market condition 209,963.08 67,374.98 65
Company age 8.32 0.59 65
R&D intensity 88.45 10.64 65
ICT
Solidity 40.91 3.44 206
Export intensity 17.32 2.11 206
Venture capitalist 0.41 0.03 206
Future R&D investments
related to company balance 3.95 1.11 206
Hot market condition 701,482.52 161,256.96 206
Company age 8.29 0.41 206
R&D intensity 48.22 3.77 206
ALL
DATA Solidity 43.38 2.72 271




related to company balance 12.07 8.74 271
Hot market condition 583,590.41 124,214.71 271
Company age 8.30 0.34 271
R&D intensity 57.87 3.97 271
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Export intensity and exports
Finland is a small player in a world scale and like Virtanen (1996) is his study has concluded, 
the growth opportunities in Finland many times are based on international activity i.e. exports. 
Exports are used in the regressions both proportionally and in absolute figures.
Future project R&D investments related to company balance and future project R&D 
investments
If earlier R&D investments were considered as growth factors, it would be natural to suggest 
that also future R&D money is relevant especially when future growth is considered. It could 
be also argued that past R&D investments are not as effective measure since it is a sunk cost 
and perhaps in some cases in ICT already realized commercially. Earlier R&D is also in many 
cases formed from different projects and is perhaps not as effective as the R&D investment 
which is directly aimed at to realize the project-specific potential at the target year. The 
independent variable is formed by dividing the future R&D investment of the project by 




Summary statistics of the Independent and Control Variables in Model 2
The table shows the means (Means) and standard error (Std error) for the independent and control variables. 
Exports = yearly exports; Venture capitalist = whether the company has venture capitalist involved (0 = no, 1= 
yes); Future R&D investments = Project related future R&D investment; Hot market condition = revenue 
increase 1999-2002 or in case of no data from that period: longest period possible; Company age = age of 
company in year 2004; R&D costs = yearly reported R&D costs.
Mean Std. error N
BIO




investments 1,882,426.67 375,376.10 70
Hot market condition 235,827.14 70,128.92 70
Company age 8.04 0.56 70
R&D costs 2,525,157.14 453,075.60 70
ICT
Exports 619,514.56 140,212.90 206
Venture capitalist 0.41 0.03 206
Future R&D
investments 603,274.14 58,793.02 206
Hot market condition 706,122.82 161,212.96 206
Company age 8.38 0.42 206
R&D costs 750,252.43 13,832.45 206
ALL DATA
Exports 536,202.90 108,484.27 276
Venture capitalist 0.49 0.03 276
Future R&D
investments 927,696.88 109,619.18 276
Hot market condition 586,844.93 122,170.29 276
Company age 8.29 0.35 276
R&D costs 1,200,409.42 192,774.35 276
Hot market condition
The hot market condition variable is formulated in order to see whether earlier development 
of company’s businesses have effect on their views of future prospects. The variable is 
formed by deducting from 2002 sales the sales from 1999. In case the company is formed 
later on, or the data is incomplete for some other reason, the period under examination is the
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longest possible between 1999-2002. The actual revenue increase is thus expected to be 
higher for companies with high future growth prospects. Special group to be studied are 
gazelle companies i.e. the company revenue has increased 20% or more per year for three 
years (2000, 2001, 2002) and the starting level of sales has been at least 100,000 €. If the 
company fulfilled the criteria it was assigned the value of 1, if not the dummy variable was 0.
Venture capitalist
This control variable is formed to find out the possible “turbo effect” of venture capitalists 
mentioned earlier. Venture capitalist control variable is a dummy variable that is assigned the 
value 0, when company do not have venture finance, and the value 1, when the company has a 
venture finance investment. The information is gathered from the project appraisal 
memorandums of Tekes. The information is semi-structured, and it had to be in some cases 
completed from other sources like Suomen Asiakastieto Oy.
Company Age
The last independent variable used is company age. Like in the chapter 3.10 was mentioned 
young Finnish biotech firms anticipate to grow faster than the old ones. This study will try to 
verify it by utilizing age as an independent variable. The same variable will be used also in 
the ICT data to see whether similar situation is in effect also there
The independent variables in the two models are not highly correlated. Table 8 and Table 9 
below shows correlations between independent variables used in the two models.
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Table 8.
Correlations of the Independent and Control Variables in Model 1
The table indicates the correlation between the independent and control variables in Model 1. Correlations with 
statistical significance are marked with an asterisk: ** (p<0.01), * (p<0.05). The definitions of variables are 
explained in Chapter 4.5.2.
1 2 3 4 5 6
BIO 1 Solidity
2 Export intensity -0.25*
3 Venture capitalist 0.21 -0.22
4 Future R&D investments related to 
company balance
0.17 -0.07 -0.21
5 Hot market condition -0.10 0.21 -0.16 -0.04
6 Company age -0.23* 0.26* -0.17 -0.07 0.35**
7 R&D intensity -0.20 0.12 0.33** -0.13 -0.23* -0.01
1 2 3 4 5 6
ICT 1 Solidity
2 Export intensity 0.10
3 Venture capitalist
4 Future R&D investments related to
0.08 0.16*
company balance 0.05 -0.05 -0.05
5 Hot market condition 0.12 0.15* 0.28** -0.07
6 Company age -0.01 0.13* 0.00 -0.13 0.13
7 R&D intensity -0.22** 0.08 0.17* 0.01 -0.06 -0.25**
1 2 3 4 5 6
ALL
DATA 1 Solidity
2 Export intensity 0.05
3 Venture capitalist
4 Future R&D investments related to
0.12 0.07
company balance 0.06 -0.04 -0.07
5 Hot market condition 0.10 0.14 0.19** -0.02
6 Company age -0.04 0.16** -0.03 -0.04 0.14*
7 R&D intensity -0.16** 0.11 0.27** -0.05 -0.09 -0.18**
In the first model the independent variables is mostly constructed so that the size factor of a 
firm is controlled. The correlations are not high in the two sub samples or in the whole data. 
This would indicate that multicollmearity is not a significant problem in this model. The 
correlations are intuitively logical. For example in the biotech data the negative correlation 
between company age and solidity would suggest that young biotech companies have higher 
solidity. Young biotech firms are heavily financed by outside equity. It is not surprising that
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hot market condition and company age have a significant positive correlation since it is quite 
clear that only older firms have established they presence in a way that they have increased 
they revenues in 1999-2002. In many younger biotech firms the revenues are very modest. 
ICT firms have inverse relation of R&D intensity with solidity and company age. It is 
possible that the first correlation is due to the fact that in the sample ICT firms have less VC 
investors involved and this could be a reason for the inverse relation of solidity and R&D 
intensity. The higher the R&D intensity the weaker the solidity if losses are not channelled to 
deferred charges and the firm is otherwise from a business point of view in a R&D phase. 
Also, older companies have normally smaller R&D intensity than the younger ones since they 
have also other expenses. Other intuitively correct correlation in the ICT data is the positive 
correlation between company age and exports. The correlations of venture capitalists are in 
the tables not directly interpretable since it is a dummy variable. Naturally, it gives an idea of 
the direction of the relation but nothing more.
Table 9.
Correlations of the Independent and Control Variables in Model 2
The table indicates the correlation between the independent and control variables in Model 2. Correlations with 
statistical significance are marked with an asterisk: ** (p<0.01), * (p<0.05). The definitions of variables are 
explained in Chapter 4.5.2.
1 2 3 4 5
BIO 1 Exports
2 Venture capitalist -0.30**
3 Future R&D investments -0.11 0.21
4 Hot market condition 0.74** -0.16 -0.09
5 Company age 0.20 -0.17 -0.06 0.35**
6 R&D costs -0.10 0.34** 0.39** -0.05 -0.08
1 2 3 4 5
ICT 1 Exports
2 Venture capitalist 0.18**
3 Future R&D investments 0.44** 0.24**
4 Hot market condition 0.51** 0.28** 0.18**
5 Company age 0.31** 0.00 0.05 0.13
6 R&D costs 0.34** 0.23** 0.34** 0.56** 0.01




2 Venture capitalist 0.09
3 Future R&D investments 0.11 0.25**





0.30** -0.03 0.00 0.14*
0.22** 0.31** 0.39** 0.38** -0.02
In the second model (Table 9) the correlations are higher but still in a reasonable level when 
multicollinearity is considered. The second model gives other interesting correlations. Firms 
with high past R&D investments will continue to invest in R&D more than other companies 
in all samples. Hot market condition and exports are in all samples highly correlated. This 
indicates that companies with higher actual revenue increase have also higher exports. This is 
even clearer in the biotech where the correlation is the highest (0.74) - companies are 
international already from the start. Cautious interpretation of the relation between venture 
capitalist and the other variables in the Model 2 would be that there seem to be to a certain 
extent a relation between hot market condition and the involvement of a venture capitalist in 
ICT data. In the Model 1 there was also a positive relation between a VC and exports. Interest 
of a venture capitalist on firms with higher revenue increase and higher export share is very 
likely.
4.6 The econometric models
In the next sections the regression models for testing the target turnover hypothesis is 
presented.
4.6.1 Model 1: Test of proportional variables on target turnover
The hypothesis H1-H7 described earlier (see Ch. 3.5-3.10) will be tested by regressing 6 
independent variables and one control variable against the target turnover (see Ch 4.4.1). The 
regression model used is a linear regression:
n=6
YtARGET TURNOVER = bQ + ^ b¡ * X + b * Cj + e (1)
including independent variables Xj to Хб and the control variables Cj:
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Xi = Solidity;
X2 = Export intensity;
X3 = Future R&D investments related to company balance; 
X4 = Hot market condition;
X5 = Company age;
Хб = R&D intensity;
Ci = Venture capitalist
The sample sizes are following: BIO (N=65), ICT (N=206) and ALL DATA (N=271).
4.5.2 Model 2: Test of variables without proportionality on target turnover
The second model is a linear regression where R&D costs, exports and future R&D 
investments are not divided by a company size measure. Five independent and one control 
variables is regressed against the same dependent variable i.e. the target turnover.
n=5
Ytarget TURNOVER = bQ + У1 b, * X. + b6 * Cx + e
i=l 1
(2)
including the independent variables Xi to X5 and the control variable Cj :
Xi = Exports;
X2 = Future R&D investments; 
X3 = Hot market condition;
X4 = Company age;
X5 = R&D costs;
Cl = Venture capitalist
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The sample sizes for the second model are: BIO (N=70), ICT (N=206) and ALL DATA 
(276). The sample sizes are smaller than the total sample presented in the Chapter 4.2 because 
cases were included list wise according to complete case approach. Both regressions are 
performed for BIO, ICT and ALL DATA. The results from the models are presented in the 
Chapter 5.
4.7 Limitations of the study
The sample size and the sample issues were dealt in the sample description part (see Ch. 4.2). 
However, the selection bias issues need to be discussed. When interpreting the results one has 
to take into the consideration the possibility that the companies especially in the ICT sample 
do not represent the whole ICT population. The biotech sample represents quite well the 
whole population of active companies. The selection period of ICT data (year 2003) is short 
and there could be reasons why certain type of companies have applied funding in a certain 
year e.g. Tekes might have a focused technology program going on and certain type of 
companies might be interested to apply when the topic matches their interest. It is also 
possible that companies with only the most risky projects apply funding. This is actually also 
very likely since Tekes specifically shares technology risk by partly funding the projects.
This also means that the risk and the return should be related and thereby target turnovers 
should be also high. However, high tech companies in general are in the forefront of the 
development and the way to stay in the frontline is the risk-taking attitude. In that respect I 
believe that the companies in the sample represent quite well the Finnish high tech 
companies.
Earlier I also mentioned that in 2003 Tekes funding for start up companies increased 
significantly compared to previous years (Tekes, 2003). This means that many of the 
companies did not have e.g. their first financial statements ready at the time of applying 
funding. In some cases the previous year’s financial statement was not ready at the time of 
applying funding reducing the cases included in the regressions. This caused a deviation 
between the projects described in the description part and the projects included in the
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regressions. However, I made a careful missing data analyses where I did not find any other 
systematic reason for missing data than those mentioned above. Naturally the number of 
companies is smaller in the regression, but there is no reason to believe that it deviates 
significantly from the total sample. Evidence for similar conclusion is possible to derive also 
from the regression results.
Measurement error is not a problem since the project specific turnover as a dependent variable 
is valid. Of course there is a possibility that the experts in Tekes could have changed for 
example the target years or the turnover level based on their expertise but it is quite rare based 
on my own experience. Tekes has also its own classification14 for target turnovers. I included 
all the target turnover estimations regardless of the classification. In my opinion the 
classification is not needed here since the level of estimated target turnover is only relevant. 
In any case the absolute majority of the cases are in one of the three classes making the 
classification problem quite marginal.
A specification problem is possible because the consideration of independent variables was 
constrained by the data available. For example patents would have been interesting to include 
in the models but it was not possible to systematically sort out accepted patents. However, 
almost all biotech companies had accepted patents or patents pending and it would probably 
not have changed the results obtained. In ICT the patent strategy is different and not always as 
vital as in biotechnology. Other specification problem was the definition of venture capitalist. 
The classification of a venture capitalist was made based on the project appraisal 
memorandums. A venture capitalist was defined to belong to the members of Finnish Venture 
Capital Association. However, also other companies investing in the spirit of FVCA were 
included based on my own judgement because it is possible that not all are members. Hot 
market condition was applied also slightly differently than originally planned. Since so many 
companies were formed after 1999 I decided to include the actual revenue increase also from 
the shorter period, which in my opinion is justified because revenue increase or decrease from 
a shorter period could also influence the future estimates of the companies. Gazelle 
examination was made partly redundant the fact that so many companies were young and in 
biotechnology only rare companies had revenue in the first place. I found 12 gazelles, nine
14 Tekes has a three stage classification for target turnover: 1. The funded project will create new turnover, 2.
The funded project will lead partly to the renewal of company turnover but is not completely new, 3. The project 
does not increase company turnover.
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from ICT and three from BIO sample. The result was somewhat expected since the companies 
were in many cases in the early phase of their development. More data would have been 
needed to validate the use of a gazelle dummy variable.
In the data processing phase I also checked that the projects were not continuations of the 
same project funded earlier in the study period. This was major concern only in biotechnology 
were projects are often funded in periods.
The normality of the variables included was studied. Variables did not correspond to the 
normal distribution but the number of observations in all three samples was high enough for 
statistical testing. Heteroscedasticity was an evident problem since as target year is further 
away, there is a wider range of possible target turnover values which leads to a non constant 
variance of the error term. The problem was most concrete in biotech firms. I tried one of the 
variance-stabilizing transformations (logarithms) but the data included so many zero values 
and even negative values (solidity) that the sample would have shrunk in size. 
Heteroscedasticity is related to the interpretation of the results and will be taken into the 
consideration when results are evaluated. Another interesting dilemma was the dependence of 
the residuals in the regression on the dependent variable. One obvious cause is the 
heteroscedasticity problem which I could not remedy but another reason is a possible absence 
of a relevant variable in the model. The relation decreased when I added the last variable in 
the models which proved to be the most significant one. The dependency of the error term 
was however still statistically significant especially in the ICT sample.
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Table 10.
The dependency of the error term with the dependent variable in Model 1-2
In the table it is easily seen the heteroscedasticity problem due to high correlations. Another reason is that the 
model might lack significant independent variables. Both problems are very common in regression analyses and 





Standardized Residual BIO Pearson Correlation 0.59"
Sig. (2-tailed) 0.000
N 271
Standardized Residual ICT Pearson Correlation 0.86"
Sig. (2-tailed) 0.000
N 271




Standardized Residual BIO Pearson Correlation 0.48"
Sig. (2-tailed) 0.000
N 276
Standardized Residual ICT Pearson Correlation 0.91"
N 276
Standardized Residual ALL DATA Pearson Correlation 0.59"
Sig. (2-tailed) 0.000
N 276
One of the most important issues before interpreting the results is to assess the correlation 
between the independent variables. Ideally the regression model should have high correlation 
between the independent and dependent variable and in the same time very small correlation 
between independent variables themselves (Hair et al., 1998). If high correlation between the 
independent variables does exist i.e. multicollinearity is affecting the results, certain remedies 
are needed because one consequence is the difficulty to determine the contribution of each 
variable due to mixed influence of the variables. In the earlier section (4.4.2) correlations 
between the independent variables were examined. In the both models correlations were not 
very high. Thus multicollinearity should not be a significant problem in the analysis. In
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addition to a simple correlation analysis, each independent variable is regressed on each other. 
In the following table is calculated the two common measures for assessing the multiple 
variable collinearity. The tolerance value and its inverse the variance inflation factor (VTF) 
indicate the degree to which each independent variable is explained by the other independent 
variables. Tolerance is the variability of the selected variable not explained by the other 
independent variables. Very small tolerance values and very high VIF values indicate high 
collinearity. According to Hair et al. (1998) a common threshold is a VEF value above 10 
which corresponds to a tolerance value of 0.10.
Table 11.
Multicollinearity of the Independent Variables
The table show the tolerance value and the variance inflation factor (VIF) for Model 1 and 2. The tolerance value 
below 0.10 and the VIF value above 10 are considered as normal thresholds when assessing multicollinearity 
(Hair et al., 1998).
Model 1 BIO ICT ALL DATA
Variable ___________________ Tolerance VIF Tolerance VIF Tolerance VIF
Solidity 0.82 1.22 0.91 1.10 0.93 1.07
Export intensity 0.86 1.16 0.89 1.12 0.92 1.09
Venture capitalist
Future R&D investments related
0.73 1.36 0.85 1.17 0.85 1.18
to company balance 0.88 1.13 0.97 1.03 0.99 1.02
Hot market condition 0.81 1.24 0.89 1.12 0.92 1.09
Company age 0.76 1.32 0.84 1.19 0.88 1.13
R&D intensity 0.76 1.32 0.84 1.19 0.84 1.19
Model 2 BIO ICT ALL DATA
Variable Tolerance VIF Tolerance VIF Tolerance VIF
Exports 0.42 2.40 0.56 1.80 0.67 1.49
Venture capitalist 0.73 1.38 0.87 1.15 0.84 1.19
Future R&D investments 0.86 1.16 0.70 1.42 0.82 1.22
Hot market condition 0.41 2.43 0.50 1.99 0.61 1.64
Company age 0.85 1.18 0.86 1.17 0.88 1.14
R&D costs 0.83 1.21 0.58 1.72 0.69 1.44
The last methodological problem discussed here is the possible effect of outliers. Especially in 
the biotech group very high target estimations concentrated on few companies i.e. 
pharmaceutical companies. These companies have very high expectations of their projects
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based on various reasons not least for the reasons of international markets and the price 
setting possibility due to patent rights. These unique projects are quite distinct with a lot of 
risky involved. However, the inclusion or exclusion of projects should be based on the 
information these unique projects can deliver, many times they could be the most interesting 
ones in the research. Pharmaceutical projects represent the outer limit of target turnover 
landscape and needs to be included in the data set. In spite of this I will come to this problem 
in the next section when the findings are reviewed because they can seriously distort the 
statistical tests.
5. Findings
In this chapter I will present the results of the regression models and discuss the possible 
reasons and the significance of the findings. The impact of venture capitalist (HI), exports 
and export intensity (H2), solidity (H3), past R&D costs and R&D intensity (H4), hot market 
condition (H5), future R&D investments and future R&D intensity (H6), and company age 
(H7) are explained in the context of company growth estimations. The results of the two 
models, Model 1 and Model 2, will be presented and the differences between the results 
considered. Next, the results are viewed in a retrospective way. For both industries I will 
present history data from earlier projects and how the project estimations have succeeded. The 
companies used in the biotech group are all companies from the regression models that had 
projects accepted for funding in 1997-1999. The past estimations of the project target turnover 
are compared to the resulted total turnover of the companies. For ICT group a similar type of 
setting is not possible but I will present another sample of ICT companies’ growth estimations 
from the past where the companies have been asked to review later on how the estimations 
have realized and what will be the outcome in the future. To be clear, the ICT sample 
companies are different companies than used in the regression model. There is no comparison 
possibility, but it should give an idea of the risk incorporated in the projects. Finally I will 
review the follow-up memorandums of the ICT projects to understand the reasoning behind 
the development. In the end of the chapter 5 the industry sector differences are discussed.
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5.1 The results of the test of proportional variables on target turnover (Model 1)
Table 12 presents the results of the Model 1. The overall fit of the first model is relatively 
low. The use of proportional variables does not explain much of the amount of variance. The 
adjusted R2 for ALL DATA is 11%, 8.7% for BIO and 16.6% for ICT. The comparison of R2 
and adjusted R2 reveals (adjusted R2 < R2) that in all samples also insignificant variables are 
included in the regression models. The confirmatory approach used usually ends up in an 
above mentioned situation. However, the exclusion of the less powerful variables does not 
significantly improve the results i.e. the stepwise regression approach is not effective either. 
Statistically significant regression coefficients are in ALL DATA export intensity, R&D 
intensity, and venture capitalist. The expected sign of these variables is in accordance with the 
sign received. In BIO sample the whole regression according the ANOVA -test is 
insignificant (sig. 0.092), the ALL DATA and ICT sample regression tests are significant 
according to ANOVA results. The ICT sample provides few statistically significant variables. 
Exports, future R&D investment related to company balance and venture capitalist are 
statistically significant at 0.01 levels.
Table 12.
Test of proportional variables on target turnover (Model 1)
The table show the regression coefficients, beta coefficients (standardized), t value, R2, adjusted R2, and the 
standard error of the estimate. The variables are explained in the Chapter 4.5.2. Statistical significance marked 













Regression coefficient -4524 -690,489 -29,817
Beta coefficient -0.003 -0.130 -0.700
t value -0.049 -0.988 -1.046
X2 Export
intensity +
Regression coefficient 288,053* 639,618 200,441**
Beta coefficient 0.132 0.171 0.289
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t value 2.194 0.189 4.276
X3 Future R&D investments related to company balance
Regression coefficient + 26,568 46,169
Beta coefficient 0.056 0.104








Beta coefficient -0.020 0.068 0.089





Beta coefficient 0.005 -0.830 -0.081





Beta coefficient 0.250 0.250 0.042





Beta coefficient 0.149 0.202 0.174
t value 0.018 1.451 2.517
R2 0.365 0.432 0.441
Adjusted R2 0.110 0.087 0.166
Standard error of the estimates 64,985,020 124,674,109 19,234,854
ANOVA -test 0.00“ 0.92 0.00“
The standard error of the three sample regressions is quite high meaning that the quality and 
the accuracy of the Model 1 do not provide the highest level of assurance but on the other 
hand it could give interesting implications on explaining the reasons behind poor overall fit. 
The Model 1 is constructed so that the company size is controlled when explaining the 
estimates given by the companies. Based on the results obtained it seems that when 
controlling the size of the companies the regression do not give support for the high target 
turnover levels. The significant variables do implicate that especially R&D costs - past and 
future - are important factors in explaining and predicting high tech company growth. Export 
intensity and VC involvement are important factors behind ICT sample growth estimations 
like earlier scientific literature suggested. In other words the first hypothesis HI venture 
capitalist is relevant like suggested (in ALL DATA and ICT), similarly the export intensity 
(H2) is relevant in ALL DATA and ICT. R&D intensity (H4) is relevant in ALL DATA and 
the future R&D investment related to company balance (H6) is important in ICT. Model 1 
does not give evidence for the relevance of company age (H7), hot market condition (H5) and
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company solidity (H3). This does not mean that the variables would not be relevant in 
predicting the company turnover levels but in the model context they do not rise up. 
Discerning reader notice that in some variables, the sign of the regression coefficient changes 
between the sub-samples and the whole sample. This has minor effect on the results because 
the change of sign appears only when the variable is not statistically powerful.
The question that arises from the Model 1 is whether the target turnover estimates are realistic 
compared to the size of the company. The ALL DATA model explains only 11% of the 
amount of variance in the target figures. Later in this chapter I will return to this question of 
realistic turnover figures by using another set of data. It has to be kept in mind that these are 
just implications that have risen during the analysis and the statistical tests do not give the 
exact answer to these questions. The only way to plunge into the problem is a retrospective 
way done later on in this study.
5.2 The test of variables without proportionality on target turnover (Model 2)
The second model (Model 2) is constructed so that the company size control is released. This 
means that R&D costs, exports and future R&D investments are included as such in the 
regression. The reasoning behind is to test whether the results obtained from the first model 
would change now when the size of the company is not controlled. The results from the 
Model 2 are presented in the Table 13. The solidity factor is not included in the Model 2 but 
a test regression with solidity included reveals that it is not relevant factor in the Model 2 
either. Solidity is not the only factor left in the shadows of more powerful predictors while 
the results of the second model turned to be very different from the first model.
The overall prediction accuracy of the second model is in ALL DATA 64.9%, in BIO 64.9 % 
and in the ICT 42.2%. The prediction accuracy is in a higher level that in the first model. The 
standard errors of the estimates decreased also substantially. In the chapter 4.6 I discussed 
also the relation of the error term with the dependent variable. There is a decrease in the 
dependency of the error term with the dependent variable in the ALL DATA and BIO in 
Model 2. While the dependency is still significant, the model 2 proved to include relevant 
factors for explaining target turnovers i.e. the release of company size factor improved the 
explaining capability of the Model 2. Obviously one of the reasons is that bigger companies
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have bigger turnover estimations. This is shortly tested empirically by adding another 
independent variable in the regression i.e. company balance as a proxy of company size. It 
showed that company size in these regressions is not statistically relevant factor. The 
reasoning behind this is that the turnover estimations are independent of the company size as 
shown next when the actual results of the Model 2 are discussed. In other words, in high tech 
world it is the future R&D investment that drives the expected turnover levels of SMEs and 
they are not dependent on the size of the company now as much as one could think. If large 
companies would be included the situation could change considerably since the target 
turnover levels are usually much higher. Target turnover levels being independent of 
company size raises naturally a question of the realistic level of the turnover estimations 
compared to the actual resources possessed by the companies. The same phenomenon is 
easily seen from the Table 6 in chapter 4.5.2 where the ratio of future R&D investments to 
company balance is enormous in BIO data (37.80) - almost forty times the size of the 
company. In ICT the same ratio is lower (3.95) due to lower level of investments needed to 
achieve R&D goals.
Table 13.
Test of variables without proportionality on target turnover (Model 2)
The table shows the regression coefficients, beta coefficients (standardized), t value, R2, adjusted R2, and the 
standard error of the estimate. The variables are explained in the Chapter 4.5.2. Statistical significance marked 




sign ALL DATA BIO ICT
Intercept -5,676,804 -10,812,792 806,943
Independent variables
X2 Exports +
Regression coefficient -2.482 -1.253 -0.033
Beta coefficient -0.072 -0.010 -0.003
t value -1.650 -0.091 -0.044
X3 Future R&D investments +
Regression coefficient 27,933“ 29,537“ 16,381“
Beta coefficient 0.818 0.813 0.655
t value 20.726 10.584 10.359
X4 Hot market condition +











Regression coefficient -60,826 330,786 -317,293
Beta coefficient -0.006 0.014 -0.091
t value -0.015 0.175 -1.588
X6 R&D costs +
Regression coefficient -0.223 1.989 -1.299**
Beta coefficient -0.011 0.066 -0.175
t value -0.268 0.842 -2.521
X7 Venture capitalist +
Regression coefficient 869,676 -7,470,725 3,982,883
Beta coefficient 0.007 -0.029 0.093
t value 0.180 -0.350 1.638
R2 0.811 0.825 0.663
Adjusted R2 0.649 0.649 0.422
Standard error of the estimates 36,834,693 67,587,635 16,033,990
ANOVA -test 0.00** 0.00** 0.00**
When analyzing the results it is quite obvious that one variable is above the others when the 
statistical significance is considered. In every three samples the future R&D investment for 
the project in question is the best individual predictor in the model. It almost seems that it 
could solely explain the majority of the variations of the target turnover. In BIO sample the 
assumption is accurate while the regression with only one variable explains 64.4% (adjusted 
R2) i.e. only 1.5 percentage units less than in the Model 2. In ICT fixture R&D investments 
could solely explain 23.7% compared to the adjusted R2 of 42.2 % in Model 2.
The other variables included in the Model 2 thus are not as powerful as the future R&D 
investments variable alone is but they still have some additional explaining power on target 
turnovers. Other statistically relevant variables in the Model 2 are R&D costs in ICT. In ICT 
also control variable venture capitalist and hot market condition are close to have some 
statistical significance.
I tested also how the exclusion of unique project estimates15 (17 projects) would show in the 
results and how the exclusion of some of the variables would change the situation. The 
majority of the excluded projects are from BIO data. The excluded variables are hot market 
condition and company age. In this reduced model the adjusted R2 is for ALL DATA 73.7%,
15 unique project = error term in pairwise diagnostics was large.
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for BIO 81.9% and for ICT 50.2%. The effect is naturally mostly seen in BIO data. The past 
R&D costs are now statistically significant in 0.01 level. In ALL DATA also exports become 
statistically relevant in 0.01 level. What this little test showed is that the statistical 
significance of a variable is dependent on these unique cases which nevertheless are not 
outliers in the traditional sense but they do have an influence on results.
The hypotheses put forward in the earlier sections 3.5 - 3.10 are discussed individually here 
for Model 2.
Venture capitalist (HI)
In the Model 2 the VC perspective is not statistically significant. Even the sign of the 
regression coefficient is mixed. The sign of the control variable in ALL DATA and in ICT is 
positive but negative in BIO. In a stepwise procedure I found a setting where VC is 
statistically significant in ICT in Model 2. The model included only future R&D investments, 
past R&D costs and exports in addition to VC control variable, i.e. the VC is effective 
variable only when the model 2 is more focused. The venture capital hypothesis is supported 
by the Model 1 in ICT.
Exports (H2)
The sign of the regression coefficient of exports is negative in Model 2. It is also negative in 
the reduced Model 2 where it is statistically significant. Quite many companies had zero 
exports and in many cases companies with the highest turnover estimates have not yet sales, 
not to mention exports. Another possible explanation is that companies with higher exports 
might concentrate more on the selling side than invest in R&D and thus have lower level of 
turnover estimates for R&D projects. The reason could be also in the model configurations 
and in the interrelations of the variables although multicollinearity is not considered as a 
problem. In the Model 1 export intensity is statistically significant in 0.01 level in ICT data 
and the sign is positive like expected.
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Solidity (НЗ)
The solidity of the companies is in a good level in general (in both sub samples over 40%). In 
the regression the solidity variable does not raise above the other factors. In fact, it is not 
statistically significant at all in both models. This would indicate that there is no link between 
growth estimations and solidity. However, there is certainly a link between high tech firms 
and high solidity in general but high solidity seems to be unable to explain high turnover 
estimations in this study context.
R&D costs (H4)
The hypothesis 4 is that the larger the yearly R&D cost or R&D intensity before making the 
turnover estimations, the higher the targeted turnover. In Model 1 the R&D intensity is 
significant in 0.01 level and the sign is positive as expected in all three groups. In Model 2 
pure R&D costs are significant only in ICT but the sign is negative. One factor influencing 
the model 2 results could be that in many cases the companies are in the early phase of their 
development and the absolute R&D costs are not yet as high as their target turnover estimates 
but in relation to their size the costs are significant as Model 1 suggests.
Hot market condition (H5)
Hot market condition is not statistically significant factor explaining companies project 
growth estimations in Model 1. In Model 2 it is statistically significant in 0.10 level 
(sig.0.092) in ICT sample, which is very interesting since the ICT data is the target data for 
this variable. The statistical significance is lower than the levels introduced for this study 
(0.01 - 0.05) but it is still worth noting. One reason which could influence the results of hot 
market condition is that the data does not include all the turnover figures for every company 
from 1999 onwards. The obvious reason is that companies are formed in many cases (BIO 
37.7% and ICT 50.4%) after 2000. Many companies in biotech does not have turnover at all 
or it is very marginal due to early phase of R&D. It seems that firms investing heavily in 
R&D do not have in many cases a history of high growth which could support their future 
growth estimations. The qualitative information studied reveal that in many cases companies
72
are creating the markets for new products. These innovations have been the basis of 
establishing the company. This means that - especially in biotech - the track record of the 
company do not stretch far.
Future R&D investments (H6)
Project related future R&D investment is very powerful variable. In the Model 1 with size 
factor included it is statistically significant only in ICT sample. In Model 2 in all three dataset 
it was highly significant. The comparison of beta coefficients reveal that especially in ALL 
DATA and BIO it had very strong position. Naturally in ICT it is also important but the 
predicting power of ICT model is lower i.e. the money companies are willing to invest is not 
as good predictor of the target turnover level than it is in BIO dataset. It is possible that the 
prediction power of the BIO data in Model 2 would be lower if more observations would be 
included but it is also good to remember that the investment environment of biotech 
companies is quite different from the environment of ICT. The investments needed to achieve 
a certain milestone in R&D in biotech are in a different level than in ICT. In that perspective 
it is natural that the future investments are more powerful interpreter in biotech than in ICT.
Company age (H7)
In Model 1 company age is not statistically significant variable, although in both sector 
samples the sign of the variable is according to expectations. It is not a significant variable in 
the Model 2 either and the sign is negative in all except in BIO dataset. In ICT data the age 
distribution of the companies leans more towards younger age category (0-4 years) than in 
BIO where company age is more evenly distributed. In BIO data also companies formed 
earlier are very eager to grow. The mixed results are not surprising in this respect.
As a conclusion from the findings of the two regression models I found some support for 
venture capital involvement, past R&D costs, exports and hot market condition. Another 
important finding is that the future R&D investments hypothesis (H6) was supported by the 
all datasets in Model 2. By incorporating the future R&D investments in the model, very high 
amount of target turnover variance is explained (ALL DATA 64. %, BIO 65.9% and ICT 
42.2%).
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The results of Model 2 are interesting from the perspective of recent study by Hermans and 
Kauranen in 2003. They study the empirical impacts of intellectual capital on future sales of 
SMEs in biotechnology. By dividing the intellectual capital on three subgroups (human, 
structural and relational) and by composing a two stage econometric model (factor analysis, 
regression analysis) of their databank of bio companies described earlier they are able to 
explain the variations of future sales in 2001-2006 with the interactions between the three 
categories roughly by 70%. As a measure of human capital they use the total personnel, the 
education of the personnel and the business experience of the CEO. The structural capital is 
measured by research and development costs, patent intensity, and the age of the firm. 
Relational capital is divided in three groups: university collaboration intensity, sources of 
equity finance and sources of capital loan finance. Hermans and Kauranen refer also to a 
paper written by Deeds (2001) who emphasize that the main source of innovation potential is 
R&D expenditure of firms. From a biotech perspective both studies give support to the 
findings from this study when comparing the amount of variance explained by Hermans and 
the variables they used and on the other hand the emphasis by Deed on R&D as a source of 
innovation potential. The elements analyzed by Hermans and Kauranen concentrate more on 
company level and are based on judgements on potential value creation of companies. Biotech 
companies without track record are difficult to value and the model they present is one 
possibility when analyzing the growth potential of the companies. The findings here focus 
more on project level and give support to the significance of R&D as a measure of company 
growth potential. It also gives an additional model for a project based valuation of the 
companies which is interesting especially when companies have many R&D projects in their 
pipelines. It is worth noting that in ICT the Model 2 is not as good explaining the turnover 
variations as it is in biotech, but future R&D investments are also in ICT very important. 
When analyzing the results, the limitations of the study should be carefully kept in mind but 
in terms of the most relevant findings, the unrealistic level of turnover estimations in Model 1 
and the future R&D investments in Model 2, the results should be quite reliable since the 
effect is so strong. The problem of heteroscedasticity and the dependency of the error term 
with the dependent variable still leave something to improve in the model design.
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5.3 Retrospective view on project turnover estimations
So far the focus has been on future turnover estimations. In the following chapters I will try to 
illustrate how the estimations and the realized development have converged.
5.3.1 Past biotechnology company turnover development compared with expected estimates
The companies chosen from biotechnology area are companies from the BIO data - the data 
used in the earlier chapters - that have also projects in a earlier time span, i.e. 1997-1999. I 
have collected the target turnover estimations of their projects funded at that time period and 
compared project turnover estimations to the entire company turnover development. The 
reason why the project based estimation are compared to the total turnover development is 
that I do not have the information of realized project turnover development. On the other hand 
by asking the companies of their project development, the analysis would be dependent on 
their view and maybe not how things have actually developed. How do I then measure from 
the total turnover the part of sales realized from projects? I will not attend to do it, because it 
is very likely that the turnover estimates done in 1997-1999 are not realized like expected in 
the first place and in addition the overall turnover level of the companies in question was low. 
In the Figure 9 is shown how the companies’ (N=19, 36% of the BIO regression model 
companies) projected sales or milestone payments and royalties for 34 projects was supposed 
to realize. Many companies have had more than one project and some of the projects have 
been financed in a row making the selection problematic. Project selection is quite 
conservative in order to avoid selecting the same project twice. Cases with reasonable 
certitude are accepted. I have also done a similar interpolation for the years between market + 
2 years and the target year than in the BIO data. The turnover is estimated to grow linearly 
until the target year. This assumption is tilted towards the probability of a success and the 
timing of revenues is probably too early when linear assumption chosen. The turnover in 
years after target year is supposed to stay in the same level as in target year due to patent 
protection. The overall setting of the graph gives an idea of how the expectations game works 
in the industry. The realized turnover development has been quite marginal compared to the 
expectations. The high turnover estimations are from pharmaceutical companies and the
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realized revenues in 1998-2002 are mainly from other companies in the industry than from 
pharmaceutical companies.
Figure 9.
Project estimations of biotech companies (N=19) with 34 projects in 1997 
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Hermans in his recent study (2004) constructed an econometric forecast model based on 
probability distribution of possible turnover outcomes of biotech companies instead relying 
on point estimates given by companies. Based on the model the annual growth of the biotech 
SMEs would be between 2002-2006 19% - 35% and the value added 125 - 309 million euros 
in 2006 with 90% probability. In the graph the growth rate of the upper bound (35%) of 
Hermans study is used to demonstrate how the total turnover of the companies would develop 
compared with the project estimations. 35% growth rate is very high in generally for an 
industry to grow as a whole. In this graph the project target estimations - put forward by the 
companies in 1997-1999 - and the total turnover development of the companies with 35% 
annual growth rate will reach each other in 2015 if three major pharmaceutical projects are 
excluded. The graph concretizes the option like feature of pharmaceutical industry' within 
biotech industry. Few blockbuster projects are expected to yield immense returns in the long
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run. The graph shows how the expectations have not realized yet in the scale planned in the 
end of 1990’s. The deviation from the expectations and the reality has brought the industry in 
the public discussion in Finland in spring 2004. Even if the assumption of linearity in the 
increase of sales between market entry years and the target year is positively skewed it is clear 
that the time-to-market has been longer than what was expected in some pharmaceutical 
companies. Naturally it is good to keep in mind that the companies analyzed here do include 
only a portion of the total population of biotechnology companies but from pharmaceutical 
companies all major sme’s are included. In other words it describes quite well how 
pharmaceutical companies have planned their market entry. The development of turnover 
estimations is dependent on few projects with extremely high expectations. When three major 
projects are excluded, the situation changes fundamentally; the estimated turnover decreases 
drastically.
For illustrative purposes the turnover estimates from the regression model (BIO data) is added 
in the graph since the company data from 1997-1999 is a subset of companies from the BIO 
data. In the BIO sample the turnover estimations are made in 07/2002 - 12/2003. The level of 
turnover of BIO data in the graph is higher than in the projects funded 1997-1999 because of 
higher number of projects funded. However, in the individual project estimations the target 
turnover figures have decreased in the drug development projects. Some of the projects have 
received funding in both time periods and the same trend is seen also in these cases. This 
indicates that in the early phase of the industry development the target estimates where higher 
in the pharmaceutical projects. Also the timing of market entry has postponed in the 
blockbuster projects. In spite of the problems the pharmaceutical industry has faced, there are 
still many projects where the expectations are high. In terms of whether the projects will 
succeed or not, the time is not yet right to make conclusions. The development time of a R&D 
project in pharmaceuticals is generally considered to take a decade. Projects started in 1997 
should have penetrated the markets in 2007. The data show a similar trend from the project 
estimations. The two peaks in target turnovers are in 2007 and 2010 for projects funded in 
1997-1999. For BIO data the common target year is 2009-2010. The estimates made by Tekes 
are considerably lower than the estimates of the companies but the outcome of the 
pharmaceutical projects naturally dominates also in this case.
The billion dollar question in the pharmaceutical industry is whether the companies are able 
first of all to succeed with their pipeline projects and if they can, how much will they get as
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milestone payments and finally how much will they make from royalties. The likelihood of a 
success of an individual project does not rise up from probability distributions. If 
pharmaceutical companies succeed in their projects, the growth rate of the industry could be 
higher than 19% - 35% estimated by Hermans (2004). Of course it is clear that not all the 
projects will succeed but the key question is whether the right ones succeed. Hermans and 
Ylä-Anttila (2004) have come to a conclusion that it will take 15-30 years until the value 
added of the industry as a whole could achieve the present level of electronics or the forest 
industry. It is reasonable to believe that this will be the case. The project data presented in this 
study should give also answers to the timing of the possible breakthroughs. Positive news 
from the industry has increased this spring (2004) and the proof-of-finance (POP) has been 
easier to reach than in the aftermath of the year 2000. The project data presented in this study 
should be one of the cornerstones of the industry growth in the next decade.
It is interesting to see whether biotechnology industry will be the famous “fourth pillar” of the 
Finnish economy as so many have suggested. When considering an industry as a pillar, the 
production capability is usually the measure. Similarly, Hermans and Ylä-Anttila (2004) have 
made their estimations based on very high increase in domestic production of biotechnology. 
The question left untouched is whether biotechnology is an industry where the production 
itself is important part of the strategies of Finnish companies. In the strategies of 
pharmaceutical companies it is not, in other fields like diagnostics, industrial enzymes, 
biomaterials and bioprocesses, nutrition and agribusiness probably yes.
The studies made by ETLA recently (Hermans and Ylä-Anttila, 2004) suggest that the growth 
of the industry will generate from mixing new and old e.g. forest industry and industrial 
enzymes. Another tempting collaboration is between ICT and biotechnology in its many 
forms. These are probably only few of the possible outcomes. The advancement of science is 
so rapid that it is obvious that there’s more to come. I believe that in the near future (in a 
decade at least) the Finnish biotechnology industry will be driven by biomaterial, 
pharmaceutical and diagnostic companies. Biomaterial companies are already increasing their 
sales and the future looks very promising, pharmaceutical companies like mentioned earlier 
are still in the chase of a breakthrough but already now there is seen some light in the 
pipelines. Diagnostics is in Finland very interesting sector because. Due to relative 
homogeneity of Finnish population and the health care system there are business possibilities 
waiting to be discovered.
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5.3.2 History data on realized and estimated R&D project related turnover development of 
ICTfirms
In biotechnology the focus of a retrospective view was between the overall turnover 
development and the expectations of the projects. In this chapter the view is more specific. 
The turnover estimates made in an application phase is compared to the realized development 
of the same project. Tekes follows the development of the companies after projects have 
ended. In May 2003 1827 copies of follow-up questionnaires was sent out to projects ended in 
2000. The response rate was 70.23%. Altogether 300 replies of SMEs were received. From 
ICT sector 79 responses (26.3% from all SMEs) were received. The response rate in ICT 
sector was weaker (48.8%) than in average in the whole sample. The respondents were asked 
to fill a 5 page questionnaire with questions concerning the development of the project after 
2000. They were asked to evaluate how the project had succeeded from a technological and 
commercial point of view. Respondents also evaluated how the project specific turnover 
development had succeeded in 2000-2003. In addition, they were asked again the market 
entry and target year turnover estimates for the projects. From a technological point of view 
the ICT projects succeeded well; 86.1% saw that the project had succeeded quite well, well or 
extremely well. The commercial potential of the projects was not realized as well as the 
technological objectives. 48.1% of the projects succeeded commercially quite well, well or 
extremely well but only 19% of the respondents stated that the commercialisation had 
succeeded well or extremely well. 2.5% of the respondents replied that the commercial phase 
was ahead.
The same trend is seen from the next figure (Fig. 10) where the application phase turnover 
estimate and the follow-up data is compared16. It is good to bear in mind that the projects 
analyzed here are a sample from the golden age of ICT i.e. from the end of 1990’s when the 
expectation game was highest in the industry. The data included two projects with very high 
hopes for the years to come after the turn of the century. The other one raised millions of 
euros from Finland and abroad. The initial strategy was to sell products to a totally new 
business area worldwide. Shortly after the strategy was changed to include only Europe and
16 The steep slope of the estimated turnover figures from 2003 onwards is due to hypothesis that after the target 
year of the project turnover level is zero due to short product cycle in ICT. This is probably too harsh hypothesis 
while the sales will most likely follow a gentle slope but it is difficult to determine a right slope. However, from 
2003 onwards companies have estimated quite linear curve for sales level which would indicate that the decrease 
in sales does not happen directly after the target year.
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later on the company had to decrease the staff by half. It is still expected that the target 
markets are in billion euros but in the individual company level the target has been set to a 
fraction from the original. The expectations versus reality are quite harsh while on average 
13% of the estimated sales realized in 2000-2003. When the two most prominent projects are 
excluded from the data plus one additional17 the estimated development of the turnovers is 
quite stable. Without these two projects, the realized turnover is on average 27% of the 
estimated turnover figures in 2000-2003. Both averages correspond quite well to the results 
from the qualitative questionnaire of the same follow-up study where the CEOs stated that 
19% of the projects succeeded well or extremely well. VTV18 i.e. state auditing office made a 
study in 1991 of companies financed by Tekes in the 80’s. The sample included 50 
companies. 54% of the projects had reached a commercial phase but only 22% of the 
estimated sales were realized.19 Of course the time period was different and as such not 
comparable to findings in this study but it still gives an idea where the success rate lies.
17 Also a third project was excluded because its impact in application phase was significant but the respondent 
was not able to define the turnover share of the project from the total company turnover. The project was part of 
their core business but the outcome itself was just an appliance included in their products.
18 VTV, abbreviation for Valtiontalouden tarkastusvirasto in Finnish








Follow-up of ICT company turnover development, projects ended
2000, N=75 —•—Application estimate: 2 Internet 
hype projects excluded
2 002 2 003 2 004 2 0052 000
—e— Realized turnover
—*— Follow-up estimate
—*— Application estimate all: 2 
Internet hype project included
—Tekes estimate all
—•— Tekes estimate without two 
Internet hype projects
—i— Overall turnover development of 
the companies between 2000- 
2002, N=60
In Tekes during the evaluation process the sales estimations proposed by the companies were 
lowered. In the Figure 10 it is possible to see that on average 22% of the sales estimated by 
Tekes experts was achieved. If the two Internet hype projects are excluded the percentage is 
much higher resulting to 64%. In practise this means that the companies themselves present 
extremely high growth estimates to an investor which will cut them down to a more 
reasonable level. It is reasonable to believe that the overall realized sales per cent is lower due 
to sample problems. Non-respondents include also companies that had gone bankruptcy; 7.5 
% of the companies in the ICT data (162 projects, 142 companies) had declared bankrupt 
between years 2000-2003. This would indicate that the sample is positively biased. The 
bankruptcy rate indicates also that the ICT projects were quite risky. The results are in line 
with the downturn in ICT business during years 2000-2003. One could also question whether 
only those with somewhat positive news of the projects would return the questionnaire while 
the response rate in ICT was considerably lower than in the whole sample. However, it is 
easily seen that the success or failure of few star projects has a significant impact on the
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return the investor - in this case Tekes - will receive. Naturally, achieved turnover level of 
companies is only one measure of the impact of R&D investments made by Tekes but it is 
certainly one of the most important when comparing the investment of 9,5 million euros to the 
results obtained from the 79 ICT R&D projects studied here.
In the follow-up study the estimations made in 2003 for the last two years are 43% and 41% 
from the original estimations. This means that the CEO’s of the companies have decreased 
substantially their estimates for forthcoming years. The starting point estimates have been 
overly positive in contrast to realized development. The estimates for the future in this 
checkpoint are more cautious. The shortest line in the graph presents the overall turnover 
development of the companies 2000-2002. The level of the realized total sales level indicates 
that the R&D project outcomes have had a marginal effect on companies total turnover i.e. in 
the aggregate level the influence has not been significant, only 11-14% yearly20.
The reasons for the lower realized turnover development are various. The R&D phase was 
longer than expected, marketing strategy failed, or the value chain was too complicated in the 
end. Other reason mentioned were problems with the customer. Key customer withdrew from 
the project and in some cases the project was not able to solve the problems customer had. 
Also the market penetration to foreign markets was difficult. The weak market situation in 
ICT in 2000-2003 weakened the market entry possibilities of the projects. According to 
responses also one important factor affecting the project outcome was the resigning of key 
personnel. In some cases markets were not mature yet for the project outcomes. Also the lack 
of standards was seen problematic. One very common explanation was the lack of financial 
resources which either had stopped the development or slowed it down. In this context it is 
quite understandable that 46.9% of the companies respondent that the significance of Tekes 
was great or extremely great for the individual company.
This small ICT sample illustrates quite well the overall development of the industry after the 
hype years. The sector had high hopes in the end of the previous decade and after year 2000 
has suffered from the overall market downturn and in addition the ICT sector itself has been 
quite weak in Finland. There is only a small group of very successful telecommunication 
companies and the software business itself is very competitive and the companies involved
20 75 projects included 67 companies of which 60 companies had informed their revenue figures to the Suomen 
Asiakastieto Oy.
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are quite small. This sample is illustrative of the expectation game in the high-tech business 
since new technology combined with overall market bubble will produce extremely high sales 
estimates. Typically for this sector only few star companies are expected to do a major part of 
the sales estimates. In this case they did not live up to the expectations - at least not yet.
5.4 The expectation game: the comparison of the two high tech industries based on the results
Naturally the overall economic impact of ICT companies on Finnish economy is totally 
different than biotechnology’s so far. In Figure 11 is the industrial production of electronics 
(elektroniikkateollisuus), machine and metal industry (kone- ja metallituoteteollisuus), forest 
industry (sellu- ja paperiteollisuus) and partly estimated development of biotechnology 
industry (bioteollisuus). The estimated growth of biotechnology done by Hermans and Ylä- 
Anttila from a value added point of view is quite marginal until 2006 although the annual 
growth rate is projected to be for the whole sector about 10-18 per cent. The impact of ICT 
industry in the graph without Nokia would be totally different.
Figure 11.
Industrial production in Finland divided in industrial branches 1948-2002, in 2000
prices, billion €.
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Source: Hermans and Ylä-Anttila (2004).
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The role of large companies is very significant when the growth of industries is studied. This 
means that also biotech industry needs significant industrial partners. Orion is a natural 
partner for small biotechnology firms. The problem is that Finland does not have big pharma 
companies - in a global scale Orion is relatively small company. One possible outcome in 
biotechnology in Finland is that the foreign big pharma companies buy small companies. 
From a production point of view I think that even if the SME companies in biotech could 
grow in Finnish ownership or under foreign multinational company, the development to the 
production scale will happen somewhere else. I would expect that some of the biomaterial, 
pharmaceutical or diagnostic companies will grow to well known R&D firms which will first 
licence its products out to the big pharma but after few or even one breakthrough starts to take 
its projects further away.
The ICT sector on the other hand is in a very interesting phase after the high growth of the 
1990’s and the turbulent years of 2000-2003. The ICT sector in a European scale has received 
positive news in 2004 and it is expected that the market forecast is now better than in previous 
few years. However, the market situation is challenging for ICT companies since realized 
sales have been under expectations. Similarly as in our research also now in summer 2004 
some of the ICT firms are doing very well and the majority is suffering from trade cycles.
Both ICT and biotechnology industries in Finland are in an important phase. The 
biotechnology firms are waiting for major licensing deals to be signed and on the other hand 
to reach the proof-of-finance from investors. ICT industry is not anymore an emergent 
industry in Finland if measured by industrial production. With the help of Nokia the industry 
has gained a strong foothold in Finland. The question raised in Finland is nowadays whether it 
is useful to continue to support the biotechnology sector or concentrate on those areas where 
we have established position (e.g. ICT and forest industry) and especially where we have 
comparative advantage. The question is important because the biotechnology is heavily 
dependent on government support (Sitra, Tekes) and without their financial resources the 
companies are incapable to operate. The question should not be whether government will 
stop its finance on biotechnology but how to find the best fit in Finnish standards. 
Biotechnology is promising new area and Finland as an internationally well-known high 
technology nation could make use of its reputation also in biotechnology.
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The expectations in biotechnology are very high but actually they are extremely high only in 
pharmaceuticals. The risk inhibited in pharmaceutical projects is high as are the investments 
needed to realize target turnovers. It is clear that those targets are not possible to be realized 
depending solely on government support. Collaboration agreements with the big pharma is a 
necessarily path for small Finnish bio companies. The comparative advantage changes in 
time, it is possible that biotechnology could be part of it some day but without domestic large 
company in international scale the path is co-operation with the global players. The 
expectation game in the Finnish pharmaceutical companies is rising. The industry needs 
breakthrough deals in order to justify used public support. As was shown earlier on, the R&D 
pipeline of pharmaceutical companies have promising projects which should materialize 
within 3-6 years. The situation is easier in the ICT for many reasons. The industry has 
produced already its Nokia. Finland is known for its ICT, which - for example - facilitates 
foreign investments. Promising companies in ICT will prove the expectations right in a 
shorter interval than in biotechnology. Biotechnology is a game for big players but also 
smaller countries can survive like Sweden has demonstrated. You just have to prove the 
expectations right.
6. Conclusions
The focal point of this study was the expectation game of the two high technology sectors. 
Both ICT and biotechnology are considered as high technology industries with high growth 
potential. The data was gathered from the database of the National Technology Agency of 
Finland, Tekes. The study aimed at creating an econometric model which could explain the 
high turnover estimates of the companies which usually do not have a sufficient track record 
to back up the estimations put forward. The second challenge was to find out whether the 
revenue estimations have been realistic.
The results obtained show that the revenue estimations made by the companies are unrealistic. 
The first econometric model created (Model 1) supports the conclusion. When exports, 
involvement of a venture capitalist, past R&D expenses, future R&D investments are 
proportional to company size, the model explains in ALL DATA only 11% of the variance of 
target turnover. In ICT variables explained 16.6%. In biotech the Model 1 was not able to 
explain the turnover levels with the variables used. The results obtained from the
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retrospective data support the findings. In ICT, the Tekes follow-up data reveals that on 
average only 27% of the companies’ expected turnover level is achieved. The ICT industry in 
Finland is known for few star companies which have managed well in the expectation game 
and on the other hand the majority of the companies especially in the software industry are 
struggling to survive. The retrospective data confirms that the turnover estimates of ICT R&D 
projects ended in year 2000 where set in an unrealistic level in spite of the fact that the 
influence of few projects is considerable in the data. It is also illustrative of the Internet- 
bubble and how the views of the market potential changed after year 2000. The realized effect 
of R&D projects on total turnover of the companies was only 11-14% yearly. Realistic level 
of the turnover estimates in ICT would be 20-30% of the original estimates. Most likely the 
turnover estimates have been done without any risk-adjusted measure. The failure of the 
companies with high growth estimates raises the question of the importance of the so-called 
middle road companies, which do not have extremely high growth prospects but are on a 
steady but long growth track and fulfil their growth estimates.
In biotechnology the target years of biotechnology companies have postponed from the years 
estimated in the early years of the industry. The target level of turnover has decreased in the 
drug development companies after the high expectations in the late 1990’s. This reflects the 
overall development in other countries after year 2000. Few drug development companies 
have very high levels of target turnover which influence the industries aggregate levels 
considerable. The target turnover estimations of biotechnology have been optimistic from the 
point of view of timing and size. It is not surprising from the study point of view that the 
biotechnology companies are incurring now (summer 2004) problems. The expectation game 
was overheated in Finland in the late 90’s and it is evident now that the industry is struggling 
to show commercial results. When the expectations have not realized like estimated, the 
investors and media particularly has started to question the rationale of the investments 
especially in the pharmaceutical industry which controls the movements in aggregate level in 
industry expectations. The study shows that the expectations have postponed and especially 
the level of pharmaceutical turnover estimates has decreased but in spite of that they still 
show high expectations for the future. It is clear that some disappointments will materialize 
but it is too early to say what will be the outcome in the industry in Finland. From the current 
point of view, years 2007-2010 will be decisive for the industry while the sales of current 
projects should be in peak level. However, the industry is now facing financial restrains which 
will have significant impact on future development of the companies.
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The most important finding of the second model (Model 2) was that when the variable future 
absolute R&D investment was included, the model explained high amount of the variance of 
turnover estimates (All data 64.9%, BIO 64.9%, ICT 42.2%). This indicates that a typical 
high-tech company in the sample has high growth estimations backed by plans to invest a 
substantial amount of money on achieving the targets. The higher the future R&D investment, 
the higher the sales revenue targeted. The turnover estimations were independent of the size 
of the companies which means that future R&D investments compared to company size were 
in unrealistic levels like Model 1 suggested. One reason for high future R&D investment 
compared to company size is that companies have calculated the possible grant or debt from 
Tekes into the budget. This means that the role of Tekes is important when considering the 
possibilities of high tech companies to carry out the projects.
In the beginning, 9 research questions were put forward. From the questions 1-7,1 found 
some support for venture capital involvement, past R&D costs, exports and hot market 
condition. The most significant impact on growth prospects however had future R&D 
investments. The results are in line with the research of Gamer et al. (2002) where they 
showed that the larger the relative R&D investment, the greater the market value of the firm. 
The answer to research question 8 in biotech is that the great expectations have not realized 
yet, but they have actually postponed and decreased but still show high expectations. 
However, the presumption is that the expectations do not materialize as estimated due to 
absence of risk-adjusted measures in turnover estimates. In ICT the estimated turnover levels 
have been unrealistic; the realistic level would be 20-30 %. The answer to the last research 
question is that the major difference between the two industries is the length and level of 
expectations.
Suggestions based on the evidence found from this study concentrate on the management of 
the commercial phase of the R&D projects. Companies need to focus more resources on 
market analyses in order to have the fundamentals right in the turnover estimations. 
Technological success as such is not sufficient. Companies need to allocate more resources to 
the commercial phase of the product life cycle and Tekes needs to put more effort on 
assessing the market potential of the R&D projects and the capabilities of the SMEs to realize 
them. Tekes funding should be allocated more to the commercial side of the R&D projects but 
only in accordance with the directives of the European Union so that the public funding does
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not hamper competition between companies in the markets. Strong R&D needs viable 
commercial capabilities in order to survive. The recent actions made by Tekes are steps to the 
right direction but needs to be strengthened more also in the long run. One very important 
remark, which I would like to stress here, is that foreign venture capital investor involvement 
was scarce in both industry sectors. I believe that it is one reason for problems in commercial 
phase especially when companies are aiming for international markets
What would be an ideal type of growth oriented high tech company based on this study? The 
most promising would be a company with high share of exports i.e. a company which is 
internationally oriented, has a venture capitalist to speed up the development and invests now 
and in the future in R&D in order to keep up in the competition. On the other hand, the 
investments should be in line with the resources of the company and there should be money 
left to penetrate the markets with the outcomes of the R&D pipeline. The target of high tech 
firms is first high growth and then later on sufficient level of profitability. The results are in 
contrast with the study of Kamshad and Hay (1996) where they found that the new 
technology based firms target first profits instead of growth. One reason could be that the 
customer profile in Tekes is more growth oriented than in all population of high tech 
companies.
Future studies in the field would include a study of the success rate of the venture capitalists 
in their high tech company investments in Finland. The field in Finland is from the scientific 
point of view quite sparsely researched. The main problem is the availability of the data since 
venture capitalists do not publicly disclose information on such matters. Another interesting 
research topic would be to study in larger scale companies that have lived up to the 
expectations i.e. what have been the critical factors of success. From a Tekes point of view it 
would be also interesting to study how Tekes has succeeded in all the industry sectors.
Studies in Tekes are made possible by the accumulating knowledge of follow-up data in the 
coming years. Naturally an update of this research after few years would also be interesting 
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